WO2014144871A1 - Cytotoxic and anti-mitotic compounds, and methods of using the same - Google Patents
Cytotoxic and anti-mitotic compounds, and methods of using the same Download PDFInfo
- Publication number
- WO2014144871A1 WO2014144871A1 PCT/US2014/029463 US2014029463W WO2014144871A1 WO 2014144871 A1 WO2014144871 A1 WO 2014144871A1 US 2014029463 W US2014029463 W US 2014029463W WO 2014144871 A1 WO2014144871 A1 WO 2014144871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- group
- alkyl
- mammal
- compound
- Prior art date
Links
- 0 CC1(*)C(C2)*2CC1 Chemical compound CC1(*)C(C2)*2CC1 0.000 description 14
- ZQVZOIQRRQDNFC-TWOYKZDZSA-N CC(C)[C@@H](/C=C(\C)/C(NS(Cc1c(C)cccc1)(=O)=O)=N)N(C)C([C@H](C(C)(C)C)NC([C@H](C(C)(C)c1ccccc1)N(C)C)=C)=O Chemical compound CC(C)[C@@H](/C=C(\C)/C(NS(Cc1c(C)cccc1)(=O)=O)=N)N(C)C([C@H](C(C)(C)C)NC([C@H](C(C)(C)c1ccccc1)N(C)C)=C)=O ZQVZOIQRRQDNFC-TWOYKZDZSA-N 0.000 description 1
- UBIXBJDZNKCENM-UHFFFAOYSA-N CCC1=CC=C(C)CC1 Chemical compound CCC1=CC=C(C)CC1 UBIXBJDZNKCENM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/02—Monothiocarboxylic acids
- C07C327/04—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/06—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/06—Compounds containing sulfur atoms only bound to two nitrogen atoms
- C07C381/08—Compounds containing sulfur atoms only bound to two nitrogen atoms having at least one of the nitrogen atoms acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to biologically active compounds, compositions comprising the same, and methods of using such biologically active compounds and compositions for the treatment of cancer and other diseases.
- Hemisasterlin a stable tripeptide obtained from marine sponges that causes microtubule depolymerization and mitotic arrest in cells.
- Hemisasterlin consists of unusual and highly congested amino acids, features thought to contribute to its activity.
- a number of groups have modified particular structural elements of hemiasterlin to evaluate structure-activity relationships and assess the activity of hemiasterlin analogs.
- Zask et al. (J Med Chem, 47:4774-4786, 2004) also report that amide analogs prepared using simple cyclic and acyclic amines exibit significantly reduced potency (reductions of one to three orders of magnitude).
- Zask et al (Bioorganic & Medicinal Chemistry Letters, 14:4353-4358, 2004) report that the addition of esterified cyclic amino acids at the carboxy-terminus yields tetrapeptide analogs with prolyl-like ester-containing termini, some of which exhibit potency comparable to parent compound in a tested cancer cell line.
- cytotoxic and anti-mitotic compositions are highly desired for the treatment of a number of devastating disorders, including cancer. While a wide variety of hemiasterlin analogs have been generated, many, including a wide variety of compounds with modifications at the carboxy terminus, exhibit reduced potency that limits utility in methods of medical treatment.
- the present disclosure is directed to biologically active compounds, compositions comprising the same, and methods of using such compounds and compositions.
- Ri and 2 are independently selected from the group consisting of: H and a saturated or unsaturated moiety having a linear, branched, or non-aromatic cyclic skeleton containing one to ten carbon atoms, and the carbon atoms are optionally substituted with: -OH, -I, -Br, -CI, -F, -CN, -C0 2 H, -( HO. -COSH, or -N0 2 ; or R, and Rs are fused and form a ring;
- R 3 and R 4 are independently selected from the group consistmg of: H, R, ArR-, or _ ? and R 4 are joined to form a ring;
- R5 is selected from the group consisting of: H, R, ArR-, and Ar;
- R5 and R 2 are fused and form a ring
- Rs is selected from the group consisting of: H, R, and ArR-;
- R? and Rg are independently selected from the group consisting of: H, R, and ArR-;
- R 9 is: wherein,
- the ring formed by joining R 3 and R 4 is a three to seven member non- aromatic cyclic skeleton within the definition of R,
- Y is defined as a moiety selected from the group consisting of: a linear, saturated or unsaturated, one to six carbon alkyl group, optionally substituted with R, A — , or X; and,
- X is defined as a moiety selected from the group consisting of:— OH,— OR, . S.— O2CR,— SH,— SR,— SOCR,— NH 2 ,— HR,— N(R) 2 , M IC OR. — NRCOR, —I, -—Br, —CI,— F,— CN,— C0 2 H, — C0 2 R,— CHO,—COR,— CONH 2 , CONHR, CON(R) 2 , COSH, COSR, NO,. S0 3 H, SOR, and
- R] 4 is selected from the group consisting of optionally substituted alkyl, optional!)' substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryls, CQR 24 , -CSR 24 . -OR 24j and -NHR 24 . wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH;
- Ar is an aromatic ring selected from the group consisting of: phenyl, naphthyl, anthracyl, pyrrolyi.
- compounds having the fol lowing structure (la) are provided:
- Ri is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocvclyi, optionally substituted heteroaryl, - COR-24, -CSR.24, -OR 24 , and -NHR 24 , wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH;
- Ri5 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optional ly substituted heterocyclyl and optional ly substituted heteroaryl;
- Ri6 is selected from the group consisting of H and C 1-6 alkyl
- Ri7 is selected from the group consisting of H and C . alkyl
- Ris and R 30 are independently selected from the group consisting of H, Ci assignment6 alkyl and -SH, with the proviso that R 18 and R 30 cannot both be H;
- R 39, R20, R21 and R-22 are independently H and C3 -6 alkyl, at least one of Ri 9 and R 20 is H; or R 2 o and R 2 ] form a double bond, I g is H, and
- R-22 is H or C1.6 alkyl
- R 2 is selected from the group consisting of H and Cj-e alkyl; or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof.
- each optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optional!)' substituted heterocyclyl and optionally substituted heteroaryl is, independently, optionally substituted with (). S. -OH, ⁇ QR? 4 , -0 2 CR. 24 , -SH, -SR. 24 , - SOCR 24 , Al l ..
- each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH
- each optionally substituted aryl and optional!' substituted heteroaryl is, independently, selected from the group consisting of optionally substituted phenyl, optionally substituted naphthy!, optionally substituted anthracyl, optionally substituted phenanthryl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted thiophenyl, optionally substituted benzofuryl, optionally substituted benzothiophenyl, optionally substituted quinoiinyl, optional!)' substituted isoquino!inyl, optionally substituted imidazolyl, optionally substituted thiazoly!, optionally substituted oxazolyl, and optionally substituted pyridinyi.
- R15 is selected from one of the follo wing structures (II), (III), (IV), (V) :
- Q is CR 25 or N
- Z is ⁇ Y R - ). ⁇ , NR 25 , S, or O;
- each R 24 is, independently, afkyf optionally substituted with halogen, -OH or -SH,
- R13 is selected from the group consisting of:
- each R 25 is, independently, selected from the group consisting of H, -OH, -R . , -OR24, -O2CR24, -SH, -SR74, -SOCR24, -NH 2 , -N 3 , -NHR 24 , -N( 2 4 ) 2 , - NHCOR 24 , -NR 24 COR 24 , -R A M .. - ⁇ , -Br, -CI, -F, -CN, -C0 2 H, -( ' ( ⁇ , M .
- each R 24 is, independently, aikyi optionally substituted with halogen, -OH or -SH.
- Rj 5 is selected from the group consisting of:
- R ⁇ is H
- R 17 is methyl
- Rig is methyl
- R3 ⁇ 4o is methyl
- any embodiment of the compounds of structure (la), as set forth above, and any specific substituent set forth herein for a R 14 , R IS , R 16 , R 17 , Ris, R ⁇ , R20 and R 30 group in the compounds of structure (la), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (I) to form embodiments of the present disclosure not specifically set forth above.
- substituents in the event that a list of substituents is listed for any particular R !4 , Ris, i6, R- 1 7, Ris, Ri 5 , R20, and R. 30 in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodiment and/or claim and that the remaining list of substituents will be considered to be within the scope of the present disclosure.
- R 2 6 is selected from the group consisting of optionally substituted alkyl, optionally substituted aikyiamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyciyl and optionally substituted heteroaryi;
- R27 is selected from the group consisting of optionally substituted alkyl, optional!)' substituted aikyiamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyciyl and optionally substituted heteroaryi;
- Rj ? is selected from the group consisting of H and C 1-6 alkyl
- Ris is selected from the group consisting of ⁇ ' ; ; . alkyl and -SH, or a stereo somer, prodrug or pharmaceuticaily acceptable salt thereof.
- each R 2 8 is, independently, alkyl optionally substituted with halogen, -OH or -SH.
- each optionally substituted aryl and optionally substituted heteroaryl is, independently, selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted anthracyl, optionally substituted phenanthryi, optionally substituted furyi, optionally substituted pyrrolyl, optionally substituted thiophenyl, optionally substituted benzofuryi, optionally substituted benzothiopheiiyi, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted imidazoiyl, optionally substituted thiazolyl, optionally substituted oxazolyl, and optionally substituted pyridinyi.
- R27 is selected from one of the follo wing structures (II), (III), (IV), (V)
- Q is CR 29 or N
- Z is C(R 2 9) 2 , NR 29 , S, or O;
- each R 2 9 is, independently, selected from the group consisting of H, - OH, -OR -. -() ⁇ ( ⁇ ! ⁇ . -SH, -SR 28 , ⁇ SQCR 28 , -NH 2 , -N 3 , ⁇ NHR 28 , -N(R 28 ) 2 , -NHCQR 28 , - NR 28 COR 28 , -I, -Br, -CI, -F, -CN, -C0 2 H, ⁇ ( ( ) > .
- each R 28 is, independently, alkyl optionally substituted with halogen, -OH or -SH,
- R 27 is selected from the group consisting of
- R i6 , R ! 7 and Rjg are each methyl
- Ku is H
- R 17 is methyl
- Rjg is methyl
- any embodiment of the compounds of structure (lb), as set forth above, and any specific substituent set forth herein for a R25, R26, Rie, R17, ig, ig and R 20 group in the compounds of structure (lb), as set forth above, may be mdependently combined with other embodiments and/or substituents of compounds of structure (I) to form embodiments of the present disclosure not specifically set forth above.
- the invention provides a method of making a compound having structure (I), (la) or (lb).
- a pharmaceutical composition comprising a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutical ly acceptable carrier, diluent or excipient.
- a method of using a compound having structure ( 1), (la) or ( lb), or a stereoisomer, pharmaceutically acceptable salt or prodnig thereof, in therapy is provided, in particular, the present disclosure provides a method of treating cancer in a mammal comprising administering to a mammal in need thereof an effective amount of a compound having structure 0), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition comprising a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier diluent or excipient.
- the present disclosure provides a method of inhibiting tumor growth in a mammal comprising administering to a mammal in need thereof an effective amount of a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition comprising a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure provides a method of killing cancer ceils in vitro using a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.
- the present disclosure provides a method of killing cancer cells in vivo in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition comprising a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure provides a method of increasing the survival time of a mammal having cancer, comprising administering to such mammal an effective amount of a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof or a pharmaceutical composition comprising a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- compositions comprising biologically active compounds having structure or (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, linked directly or indirectly to a targeting moiety are provided.
- (T) is a targeting moiety
- (L) is an optional linker
- (D) is a compound having structure (I), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodmg thereof.
- (D) is covalently attached to (L), if (L) is present, or (T), if (L) is not present.
- (D) is a compound having the structure (lb).
- the targeting moiety is an antibody.
- ADCs antibody-drug conjugates comprising compounds having structure (i), (la) or (lb), or a stereoisomer, pharmaceutically acceptable salt or prodmg thereof, are provided.
- the invention provides a method of making a composition having structure (VI).
- a pharmaceutical composition comprising a composition having structure (VI), or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- a method of using a composition having structure (VI) in therapy is provided.
- the present disclosure provides a method of treating cancer in a mammal comprising administering to a mammal in need thereof an effective amount of a composition having structure (VI) or a pharmaceutical composition comprising a composition having structure (VI) and a pharmaceutically acceptable carrier diluent or excipient.
- the present disclosure provides a method of inhibiting tumor growth in a mammal comprising administering to a mammal in need thereof an effective amount of a composition having structure (VI) or a pharmaceutical composition comprising a composition having stnicture (VI ) and a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure provides a method of killing cancer cells in vitro using a composition having structure (VI).
- the present disclosure provides a method of killing cancer cells in vivo in a mammal, comprising administering to a mammal in need thereof an effective amount of a composition having structure (VI) or a pharmaceutical composition comprising a composition having structure (VI) and a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure provides a method of increasing the survival time of a mammal having cancer, comprising administering to a mammal in need thereof an effective amount of a composition having structure (VI) or a pharmaceutical composition comprising a composition having structure (VI) and a pharmaceutically acceptable carrier, diluent or excipient.
- Figure 1 shows summarized cytotoxicity data (EC 50 ) for each of Componds A ⁇ E for two cell lines (HCC1954 and Jurkat).
- Figure 2 shows a cytotoxicity data plot for Compound A on two cell lines (I ICC 1954 and Jurkat).
- Figure 3 shows a cytotoxicity data plot for Compound B on two cell lines (HCC1954 and Jurkat).
- Figure 4 shows a cytotoxicity data plot for Compound C on two cell lines (HCC 1954 and Jurkat).
- Figure 5 shows a cytotoxicity data plot for Compound D on two cell lines (HCC 1954 and Jurkat).
- Figure 6 shows a cytotoxicity data plot for Compound E on two cell lines (HCC 1954 and Jurkat).
- FIG. 7 shows a ceil kill curve on HCC 1954 cells in vitro with the antibody-drag conjugates: T-LC-SPDP-A (Trastuzumab, LC-SPDP linker, Compound A) and T-SMCC-A. (Trastuzumab, SMCC linker, Compound A). EC 50 values are shown in the figure.
- Figure 8 shows a cell kill curve on HCC 1954 cells in vitro with the antibody-drug conjugates: T- SPDP-B (Trastuzumab, LC-SPDP linker, Compound B) and T-SMCC-A (Trastuzumab, SMCC linker, Compound B). EC 50 values are shown in the figure.
- Figure 9 shows a cell kill curve on HCC 1954 cells in vitro with the antibody-drug conjugate: T-LC-SPDP-C (Trastuzumab, LC-SPDP linker, Compound
- Figure 10 shows a cell kill curve on HCC 1954 ceils in vitro with the antibody-drug conjugates: T-MCvcPABC-85 (Trastuzumab, MCve PABC linker, Compound 85), T-MCvcPABC-77 (Trastuzumab, MCvc PABC linker, Compound 77) and T-MCVGPABC-80 (Trastuzumab, MCvc PABC linker, Compound 80).
- EC 50 values are shown in the figure.
- Figure 11 shows a cell kill curve on BxPC-3 cells in vitro with the antibody-drug conjugate C-MCvcPABC-77, (Cetuximab, MCvc PABC linker, Compound 77), and a cell kill curve on HPAF-II cells in vitro with the antibody-drug conjugate C-MCvcPABC-77, (Cetuximab, MCvc PABC linker, Compound 77).
- EC 50 values are shown in the figure.
- Figure 12 shows a cell kill curve on HCC 1954 cells in vitro with the antibody-drug conjugates: T-MCvcPABC-77, (Trastuzumab, MCvc PABC linker, Compound 77), T-MCvcPABC-85 , (Trastuzumab, MCvc PABC linker, Compound 85), T-MCvcPABC-58, (Trastuzumab, ViCve PABC linker, Compound 58), and T- MCvcPABC-63, (Trastuzumab, MCvc PABC linker, Compound 63).
- EC 5 o values are shown in the figure.
- FIG. 13 shows a ceil kill curve on NCI-N87 cells in vitro with the antibody-drug conjugates: T-MCvcPABC-77, (Trastuzumab, MCvc PABC linker, Compound 77), T-MCvePABC-63, (Trastuzumab, MCvc PABC' linker, Compound 63), T-MCvcPABC-85, (Trastuzumab, MCvc PABC linker, Compound 85), T- MCvcPABC-77, (Trastuzumab, MCvc PABC linker, Compound 77), and T- MCvcPABC-80, (Trastuzumab, MCvc PABC linker, Compound 80).
- EC 50 values are shown in the figure.
- Figure 14 shows the in vivo results of administration of Compound F, Compound 14, or Compound 23 on tumour volume in female athymic nude mice with established tumours.
- Figure 15 shows the in vivo results of administration of antibody-drug conjugate T-MCC-DMl (Trastuzumab, MCC linker, maytansinoid DM1) at varied dosages as indicated, or T-MCvcPABC-77 at varied dosages as indicated, on tumour volume in female NOD/SCID Gamma mice with established tumours.
- T-MCC-DMl Trastuzumab, MCC linker, maytansinoid DM1
- Figure 16 shows the in vivo results of administration of antibody-drug conjugate T-MCvcPABC-63 at 3mg/kg, or T-MCvcPABC-77 at 3mg/kg, on tumour volume in female NOD/SCID Gamma mice with established tumours.
- Figure 17 shows a cell kill curve on HCC 1954 cells in vitro with the antibody-drug conjugates: T- SPDP-14G (Trastuzumab, LC-SPDP linker, Compound 140) and T-SMCC-140 (Trastuzumab, SMCC linker, Compound 140).
- T- SPDP-14G Trastuzumab, LC-SPDP linker, Compound 140
- T-SMCC-140 Trastuzumab, SMCC linker, Compound 140
- Compound 140 is linked through the side chain of its N-terminal amino acid.
- EC50 values are shown in the figure.
- Figure 18 shows a cell kill curve on HCC 1954 cells in vitro with the antibody-drug conjugates: T- SPDP-142 (Trastuzumab, LC-SPDP linker, Compound 142) and T-SMCC-142 (Trastuzumab, SMCC linker, Compound 142).
- T- SPDP-142 Trastuzumab, LC-SPDP linker, Compound 142
- T-SMCC-142 Trastuzumab, SMCC linker, Compound 142
- Compound 142 is linked through the side chain of its N-terminal amino acid.
- EC 50 values are shown in the figure.
- Figure 19 shows a ceil kill curve on HCC1954 cells in vitro with the antibody-drug conjugates: T-MCvcPABC-58, (Trastuzumab, MCvc PABC linker, Compound 58), and T-MCvcPABC-41 , (Trastuzumab, MCvc PABC linker, Compound 41), and shows a cell kill curve on NCI-N87 cells in vitro with the antibody-drug conjugates: T-MCvePABC-58, (Trastuzumab, MCvc PABC linker, Compound 58), and T-MCvcPABC-41 , (Trastuzumab, MCvc PABC linker, Compound 41).
- Compound 41 is linked through the side chain of its N-terminal. amino acid.
- Compound 58 is linked through the side chain of its N-terminal amino acid.
- EC50 values are shown in the figure. EC50 values are shown in the figure.
- Niro refers to the -NO?, substituent.
- Alky refers to a straight or branched hydrocarbon chain substituent consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (Cj-Ci 2 alkyl), preferably one to eight carbon atoms (C t -Cg alky! or one to six carbon atoms (Cj-Ce alkyl), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, //-propyl, 1-methylethyl (iso-propyl), «-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-niethy hexyi, ethenyl, prop-l-enyl, but-l-enyl, pent-l-enyl, penta-l,4
- Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a substituent group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenyiene, n-butenylene, propynylene, «-butynylene, and the like.
- the alkylene chain is attached to the rest of the molecule through a single or double bond and to the substituent group through a single or double bond.
- alkylene chain can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.
- Alkoxy refers to a substituent of the formula -O a where R a is an alkyl substituent as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.
- Alkylamino refers to a substituent of the formula -NHRa or -NRJla where each R a is, mdependently, an alkyl substituent as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.
- Thioalkyl refers to a substituent of the formula ⁇ SRa where R a is an alkyl substituent as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
- Aryl refers to a hydrocarbon ring system substituent comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
- the aryl substituent may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
- Aryl substituents include, but are not limited to, aryl substituents derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fiuorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
- Aralkyl refers to a substituent of the formula -Rb-Rc where b is an alkylene chain as defined above and R c is one or more aryl substituents as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.
- Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon substituent consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
- Monocyclic substituente include, for example, cyclopropyl, eyeiobutyi, cyclopentyl, cyc!ohexy!, cycloheptyl, and eyelooctyl.
- Polycyclic substituents include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyi, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted.
- Cyc3.oalkylal.kyl refers to a substituent of the formula where R ⁇ j is an alkylene chain as defined above and R g is a cycloalkyl substituent as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
- fused refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the disclosure.
- the fused ring is a heterocyclyl ring or a heteroaryl ring
- any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
- Halo or halogen refers to bromo, chloro, fluoro or iodo.
- Haloalkyl refers to an alkyl substituent, as defined above, that is substituted by one or more halo substituents, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-dif!uoroethyl, 3-bromo-2-iluoropropyl, 1 ,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
- Heterocyclyl or “heterocyclic ring” refers to a stable 3- to 18-membered non-aromatic ring substituent which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- the heterocyclyl substituent may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl substituent may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl substituent may be partially or fully saturated.
- heterocyclyl substituents include, but are not limited to, dioxolanyl, thieny[[l,3]dithianyl, decahydroisoquinolyl, imiclazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidirryl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, tbiamorpholinyl, 1-oxo-thio
- N-heterocyclyi refers to a heterocyclyi substituent as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyi substituent to the rest of the molecule is through a nitrogen atom in the heterocyclyi substituent. Unless stated otherwise specifically in the specification, a N-beterocyclyl group may be optionally substituted.
- Heterocyclylalkyl refers to a substituent of the formula -RbR e where Rb is an alkylene chain as defined above and R e is a heterocyclyi substituent as defined above, and if the heterocyclyi is a nitrogen-containing heterocyclyi, the heterocyclyi may be attached to the alkyl substituent at the nitrogen atom. Unless stated othenvise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.
- Heteroaryl refers to a 5- to 14-membered ring system substituent comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
- the heteroaryl substituent may be a monocyclic, bicyciic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl substituent may be optionally oxidized; the nitrogen atom may be optionally quaternized.
- Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazoiyl, benziiidolyl, benzodioxoiyl, benzofuranyl, benzooxazolyl, benzothiazoiyl, benzothiadiazolyi, benzo[&][l,4]dioxepinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxoiyl, benzodioxinyl, benzopyranyl, benzopyranonyi, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[ 1 ,2-a]pyridinyl, carbazolyl, cinnolmyl, dibenzomrany
- N-heteroaryl refers to a heteroaryl substituent as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl substituent to the rest of the molecule is through a nitrogen atom in the heteroaryl substituent. Unless stated otherwise specifically in the specification, an N-heteroaryl group may be optionally substituted.
- Heteroarylalkyl refers to a substituent of the formula -RbR f where 3 ⁇ 4 is an alkylene chain as defined above and R f is a heteroaryl substituent as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
- substituted means any of the above groups ⁇ i.e., alkyl, alkylene, aikoxy, alkylamino, thioalkyl, aryl, araikyi, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxy!
- a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups
- a nitrogen atom in groups such as azides, amines, amides, alkylamines, dialkylamines, arylamines, aikylarylamines, diarylammes, N-oxides, imides, and enamines
- a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups.
- Substituted also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple -bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyi, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitri!es.
- a higher-order bond e.g., a double- or triple -bond
- nitrogen in groups such as imines, oximes, hydrazones, and nitri!es.
- R g and are the same or different and independently hydrogen, alkyl, alkoxy, a!ky!amino, thioalkyl, aryl, aralkyl, cycloalkyl, cycioalkylalkyl, haloalkyl, heterocyciyl, N-heterocyclyl, heterocyciylalkyl, heteroaryl, iV-heteroaryl and/or heteroarylalkyl.
- Substituted further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxy!, irnino, nitro, oxo, thioxo, halo, alkyl, alkoxy, aikylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycioalkylalkyl, haloalkyl, heterocyciyl, /Y-heterocyclyi, heterocyciylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
- each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
- protecting group refers to a labile chemical moiety which is known in the art to protect reactive groups including without limitation, hydroxyl and amino groups, against undesired reactions during synthetic procedures. Hydroxyl and amino groups which protected with a protecting group are referred to herein as “protected hydroxyl groups” and “protected amino groups”, respectively. Protecting groups are typically used selectively and/or orthogonally to protect sites during reactions at other reactive sites and can then be removed to leave the unprotected group as is or available for further reactions. Protecting groups as known in the art are described generally in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999).
- Groups can he selectively incorporated into compounds of the present disclosure as precursors.
- an amino group can be placed into a compound of the disclosure as an azido group that can be chemically converted to the amino group at a desired point in the synthesis.
- groups are protected or present as a precursor that will be inert to reactions that modify other areas of the parent molecule for conversion into their final groups at an appropriate time. Further representative protecting or precursor groups are discussed in Agrawal, et al, Protocols for Oligonucleotide Conjugates, Eds, Humana Press; New Jersey, 1994; Vol. 26 pp. 1-72. Examples of "hydroxy!
- protecting groups include, but are not limited to, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1- ethoxyethyl, 1 ⁇ (2 ⁇ ehloroethoxy)ethyl, 2-trimethyLsilylethyl, p-chlorophenyl, 2,4- dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, tri henylmethyl, trimethylsilyl, triethylsilyl, t-butyldimethyisiiyl, t-butyldiphenylsilyl (TBDP8), triphenylsilyl, benzoylformate, acetate, chloroacetate, trichloroacetate, tri- fiuoroacetate, pivaloate, benzoate, p-phenyibenzoate, 9-tluoren
- amino protecting groups include, but are not limited to, carbamate-protecting groups, such as 2-trimethylsiiyiethoxycarbonyI (Teoc), 1 -methyl- l-(4-biphenylyl)ethoxycarbonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyi (Alloc), 9-fluorenylmethyloxycarbonyi (Fmoc), and benzyl- oxycarbonyl (Cbz); amide protecting groups, such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenyiacetyl; sulfonamide-protecting groups, such as 2- nitrobenzenesuifonyl; and imine and cyclic imide protecting groups, such as phthalimido and dithiasuccinoyl.
- carbamate-protecting groups such as 2-trimethylsiiyiethoxycarbonyI (Teoc
- Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the disclosure.
- prodrug refers to a metabolic precursor of a compound of the disclosure that is pharmaceutically acceptable.
- a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the disclosure.
- a prodrug is rapidly transformed in vivo to yield the parent compound of the disclosure, for example, by hydrolysis in blood.
- a prodrug may be stable in plasma or blood.
- a prodrug may be targeted form of a compound of the invention.
- the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)).
- a discussion of prodrugs is provided in Higuchi, T., et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- prodrug is meant to include any covalently bonded earners, which release the active compound of the disclosure in vivo when such prodrug is administered to a mammalian subject.
- Conjugates including ADCs, as disclosed herein, are such prodrugs of compositions having structure (I), (la) or (lb).
- Prodrugs of a compound of the disclosure may be prepared by modifying functional groups present in the compound of the disclosure in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the disclosure.
- Prodrugs include compounds of the disclosure wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the disclosure is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the disclosure and the like.
- the present disclosure also meant to encompass all pharmaceutically acceptable compounds of structure (I), (la) or (lb) being isotopically-iabelled by having one or more atoms replaced by an atom having a different atomic mass or mass number
- isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ⁇ , 3 ⁇ 4, n C, 13 C, i4 C, 13 N, 15 N, 15 0, 17 0, 18 0, 3i P, 32 P, 35 S, i8 F, 36 Ci, 123 i, and l2 % respectively.
- radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
- Certain isotopically-labelled compounds of structure (I), (la) or (lb), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. " ⁇ , and carbon- 14, i.e. l4 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Isotopically-labeled compounds of structure (I), (la) or (lb) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- the present disclosure is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the present disclosure includes compounds produced by a process comprising administering a compound of this disclosure to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiol abeiled compound of the disclosure in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
- an animal such as rat, mouse, guinea pig, monkey, or to human
- “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- antibody herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
- antibody refers to a full-length immunoglobulin molecule or a functionally active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospeciflcally binds an antigen of a target of interest or part thereof.
- the immunoglobulin disclosed herein can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgGl, IgG2, ]gG3, !gG4, !gAl and IgA2) or subclass of immunoglobulin molecule.
- the immunoglobulins can be derived from any species.
- the immunoglobulin is of human, murine, or rabbit origin.
- the antibodies are polyclonal, monoclonal, multi-specific (e.g., bispecific), human, humanized or chimeric antibodies, linear antibodies, single chain antibodies, diabodies, maxibodies, minibodies, Fv, Fab fragments, F(ab') fragments, F(ab')2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR's, and epitope-binding fragments of any of the above which immunospecifically bind to a target antigen.
- Monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally- occurring mutations that may be present in minor amounts.
- Monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain (s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies (see, e.g., U.S. Pat. No.
- Monoclonal antibodies also include humanized antibodies may contain a completely human constant region and a CDRs from a nonhuman source.
- An "intact" antibody is one which comprises an antige -binding variable region as well as a light chain constant domain (CL) and heavy chain constant domains, C HI , CH2 and CH 3 -
- the constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variant thereof.
- Antibody fragments comprise a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof.
- antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; maxibodi.es; minibodi.es; and multispecific antibodies formed from antibody fragment(s).
- an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
- Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
- An antibody "which binds" an antigen of interest is one capable of binding that antigen with sufficient affinity such that the antibody is useful in targeting a cell expressing the antigen.
- a “native sequence” polypeptide is one which has the same amino acid sequence as a polypeptide derived from nature. Such native sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. Thus, a native sequence polypeptide can have the amino acid sequence of naturally-occurring human polypeptide, murine polypeptide, or polypeptide from any other mammalian species.
- intracellular metabolite refers to a compound resulting from a metabolic process or reaction inside a ceil on a composition of the invention (e.g., an antibody drug conjugate (ADC)).
- the metabolic process or reaction may be an enzymatic process such as proteolytic cleavage of a peptide linker of the subject composition, or hydrolysis of a functional group such as a hydrazone, ester, or amide within the subject composition.
- intracellular metabolites include, but are not limited to, antibodies and free drug which have been separated intracellulariy, i.e., after entry, diffusion, uptake or transport into a cell (e.g., by enzymatic cleavage of an A DC by an intracellular enzyme).
- intracellulariy cleaved and intracellular cleavage refer to metabolic processes or reactions inside a ceil on a composition of the invention whereby the covalent attachment, e.g., the linker (L), between the drug moiety (D) and the targeting moiety (T) (e.g., an antibody) is broken, resulting in the free drug dissociated from (T) inside the cell.
- the cleaved moieties of the subject compositions are thus intracellular metabolites (e.g., T, T-L fragment, D-L fragment, D).
- the invention provides compositions that are cleavage products of a composition having structure (VI), which cleavage products include compositions comprising structure (1), (la) or (lb), or stereoisomers thereof.
- the linker (L), between microtubule dusrupting peptide toxin (PT) and the targeting moiety (T) may be broken intracellulariy, resulting in the PT dissociated from (T) inside the cell.
- the cleaved moieties of the subject compositions are thus intracellular metabolites (e.g., T, T-L fragment, PT-L fragment, PT).
- the invention provides compositions that are cleavage products of a composition having structure (Vll), which cleavage products include compositions structure (I), (la) or (lb), or stereoisomers thereof.
- extracellular cleavage refers a metabolic process or reaction outside a cell on a composition of the invention whereby the covalent attachment, e.g., the linker (L), between the drug moiety (D) and the targeting moiety (T) (e.g., an antibody) is broken, resulting in the free drug dissociated from (T) outside the cell.
- the cleaved moieties of the subject compositions are thus initially extracellular metabolites (e.g., T, T-L fragment, D-L fragment, D), which may move mtraceliuiarly by diffusion and cell permability or transport.
- the invention provides compositions that are cleavage products of a composition having structure (VI), which cleavage products include compositions comprising structure (I), (la) or (lb), or stereoisomers thereof.
- the linker (L), between microtubule disrupting peptide toxin (PT) and the targeting moiety (T) may be broken extracellularly, resulting in the PT dissociated from (T) outside the cel l.
- the cleaved moieties of the subject compositions are thus initial ly extracellular metabolites (e.g., T, T-L fragment, PT-L fragment, PT).
- the invention provides compositions that are cleavage products of a composition having stnicture ( VII), which cleavage products inciude compositions comprising structure (I), (la) or (lb), or stereoisomers thereof.
- “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
- Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
- optionally substituted aryl means that the aryl substituent may or may not be substituted and that the description includes both substituted aryl substituents and aryl substituents having no substitution.
- “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration (or other similar regulator agency of another jurisdiction) as being acceptable for use in humans or domestic animals.
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesuifonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyisulfuric acid, ethane- 1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulf
- “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropy] amine, trimethy] amine, diethylamine, triethylaraine, ⁇ .propylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol,
- 2-diethylaminoethanol dicyclohexylamine, lysine, argi ine, histidine, caffeine, procaine, hydrabaraine, choline, betaine, benethamine, benzathine, ethylenedi amine, glucosamine, methylgiucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, ⁇ '-ethylpiperidine, polyamine resins and the like.
- Particularly preferred organic bases are isopropy iamine, diethylamine, ethanolamine, trimetbyiamme, dicyclohexylamine, choline and caffeine.
- solvate refers to an aggregate that comprises one or more molecules of a compound of the disclosure with one or more molecules of solvent.
- the solvent may be water, in which case the solvate may be a hydrate.
- the solvent may be an organic solvent.
- the compounds of the present disclosure may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding soivated forms.
- the compound of the disclosure may be true solvates, while in other cases, the compound of the disclosure may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
- a “pharmaceutical composition” refers to a formulation of a compound of the disclosure and a medium generally accepted in the art. for the delivery of the biological!)' active compound to mammals, e.g., humans.
- a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
- Non-limiting examples of disorders to be treated herein include benign and malignant tumors; leukemia and lymphoid malignancies, in particular breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic, prostate or bladder cancer; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders, autoimmune disease, inflammatory disease, fibrosis, and infectious disease.
- leukemia and lymphoid malignancies in particular breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic, prostate or bladder cancer
- neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders autoimmune disease, inflammatory disease, fibrosis, and infectious disease.
- compositions of the invention are used to treat autoimmune disease.
- Antibodies immunospecific for an antigen of a cell that is responsible for producing autoimmune antibodies can be obtained from any organization (e.g., a university scientist or a company such as Genentech) or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques.
- useful Ligand antibodies that are immunospecific for the treatment of autoimmune diseases include, but are not limited to, Anti-Nuclear Antibody; Anti ds DNA; Anti ss DNA, Anti Cardiolipin Antibody IgM, IgG; Anti Phospholipid Antibody IgM, IgG; Anti SM Antibody; Anti Mitochondrial Antibody;
- Thyroid Antibody Microsomal Antibody; Thyroglobulin Antibody; Anti
- antibodies useful in the present methods can bind to both a receptor or a receptor complex expressed on an activated lymphocyte.
- the receptor or receptor complex can comprise an immunoglobulin gene superfamily member, a TNF receptor superfamily member, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein.
- suitable immunoglobulin superfamily members are CD2, CD3, CD4, CDS, CD 19, CD22, CD28, CD79, CD90, CD 152/CTLA-4, PD-1, and ICOS.
- TNF receptor superfamily members are CD27, CD40, CD95/Fas, CD134/OX40, CD137/4-1BB, TNF-R1, TNFR-2, RANK, TACI, BCMA, osteoprotegerin, Apo2/TRAIL-RI, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-3.
- Non-limiting examples of suitable integrins are CD1 la, CD l ib, CD 11c, CD] 8, CD29, CD4I , CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD103, and CD 104, Non- limiting examples of suitable lectins are C-type, S-type, and I-type lectin.
- the Ligand is an antibody that binds to an activated lymphocyte that is associated with an autoimmune disease.
- Immunological diseases that are characterized by inappropriate activation of immune ceils and that can be treated or prevented by the methods described herein can be classified, for example, by the type(s) of hypersensitivity reaction(s) that underlie the disorder. These reactions are typically classified into four types: anaphylactic reactions, cytotoxic (cytolytic) reactions, immune complex reactions, or cell-mediated immunity (CMI) reactions (also referred to as delayed-type hypersensitivity (DTH) reactions).
- CMI cell-mediated immunity
- DTH delayed-type hypersensitivity
- immunological diseases include the following: rheumatoid arthritis, autoimmune demyelinative diseases (e.g., multiple sclerosis, allergic encephalomyelitis), endocrine ophthalmopathy, uveoretinitis, systemic lupus erythematosus, myasthenia gravis.
- autoimmune demyelinative diseases e.g., multiple sclerosis, allergic encephalomyelitis
- endocrine ophthalmopathy e.g., uveoretinitis
- systemic lupus erythematosus e.g., myasthenia gravis.
- the immunological disorder is T cell-mediated, which may include activated T cells.
- ADC's or A DC derivatives can be administered to deplete such activated T cells.
- compositions of the invention may be used to treat fibrosis.
- Fibrosis can occur in many tissues within the body, typically as a result of inflammation or damage, examples include but are not limited to; Lungs, Pulmonary fibrosis. Idiopathic pulmonary fibrosis.
- Cystic fibrosis Liver, Cirrhosis; Heart, Endomyocardial fibrosis, Old myocardial infarction, Atrial Fibrosis; Others, Mediastinal fibrosis (soft tissue of the mediastinum), Myelofibrosis (bone marrow), Retroperitoneal fibrosis (soft tissue of the retroperitoneum), Progressive massive fibrosis (lungs); a complication of coal workers' pneumoconiosis, Nephrogenic systemic fibrosis (skin), Crohn's Disease (intestine), Keloid (skin), Sclerodenna/systemic sclerosis (skin, lungs), Arthrofibrosis (knee, shoulder, other joints), Peyronie's disease (penis), Dupuytren's contracture (hands,fingers) and some forms of adhesive capsulitis (shoulder).
- compositions of the invention may be used directly on certain infectious agents or pathogens, or may be used to exert a cytostatic or cytotoxic effect on a host cell that harbours or otherwise provides for the infectious agent or pathogen.
- Effective amount refers to that amount of a compound of the disclosure which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of the particular indication (e.g., cancer or tumour ceils in the mammal, preferably a human).
- the amount of a compound of the disclosure which constitutes a “therapeuticalr effective amount” will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be detennined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
- Treating covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
- a therapeutically effective amount of compound in respect of cancer treatment may reduce the number of cancer ceils; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; mhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; increase survival time; and/or relieve to some extent one or more of the symptoms associated with the cancer.
- the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
- Compounds of the present invention are preferably cytotoxic.
- efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).
- an “effective amount” in respect of a particular result to be achieved is an amount sufficient to achieve the desired result.
- an “effective amount” of drug when referred to in respect of the killing of cancer cells refers to an amount of drug sufficient to produce the killing effect.
- Solid tumors contemplated for treatment using the presently disclosed compounds include but are not limited to: sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheiiosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, E wing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer (e.g., gastrointestinal cancer), oral cancer, nasal cancer, throat cancer, squamous ceil carcmoma (e.g., of the lung), basal cell carcmoma, adenocarcinoma (
- Blood-borne cancers contemplated for treatment using the presently disclosed compounds include but are not limited to: acute lymphoblastic leukemia "ALL”, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblast ⁇ leukemia “AMI.”, acute promyelocytic leukemia “API.”, acute monoblastic leukemia, acute eiythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia "CML”, chronic lymphocytic leukemia "CLL”, hairy cell leukemia, and multiple myeloma.
- ALL acute lymphoblastic leukemia
- ALL acute lymphoblastic B-cell leukemia
- acute lymphoblastic T-cell leukemia acute myeloblast ⁇ leukemia
- AMI acute promyelocy
- Acute and chronic leukemias contemplated for treatment using the presently disclosed compounds include but are not limited to: lymphoblastic, myelogenous, lymphocytic, and myelocytic leukemias.
- Lymphomas contemplated for treatment using the presently disclosed compounds include but are not limited to: Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and polycythemia vera.
- cancers contemplated for treatment using the present!' disclosed compounds include but are not limited to: peritoneal cancer, hepatocellular cancer, hepatoma, salivary cancer, vulval cancer, thyroid, penile cancer, anal cancer, head and neck cancer, renal cell carcinoma, acute anaplastic large cell carcinoma, and cutaneous anaplastic large cell carcmoma.
- Cancers including, but not limited to, a tumor, metastasis, or other disease or disorder characterized by uncontrolled or undesired cell growth, can be treated or prevented by administration of the presently disclosed compounds.
- methods for treating or preventing cancer including administering to a patient in need thereof an effective amount of a compound disclosed herein in combination with an additional method of treatment.
- the additional method of treatment includes treatment with a chemotherapeutic agent.
- the chemotherapeutic agent is that with which treatment of the cancer has not been found to be refractor ⁇ '.
- the chemotherapeutic agent is that with which the treatment of cancer has been found to be refractory.
- the compound of the invention may be administered before, after, or at the same time as the chemotherapeutic agent.
- the additional method of treatment is radiation therapy.
- the compound of the invention may be administered before, after, or at the same time as the radiation.
- Compounds of the invention may also be administered to a patient that has undergone or will undergo surgery as treatment for the cancer.
- the compound of the invention is administered concurrently with the chemotherapeutic agent or with radiation therapy.
- the chemotherapeutic agent or radiation therapy is administered prior or subsequent to administration of compound of the invention, in one aspect at least an hour, five hours, 12 hours, a day, a week, a month, in further aspects several months (e.g., up to three months), prior or subsequent to administration of a compound of the invention.
- a chemotherapeutic agent can be administered over a series of sessions. Any one or a combination of the chemotherapeutic agents listed herein or otherwise known in the art can be administered.
- any radiation therapy protocol can be used dependmg upon the type of cancer to be treated.
- x-ray radiation can be administered; in particular, high-energy megavoltage (radiation of greater that 1 MeV energy) can be used for deep tumors, and electron beam and orthovoltage x-ray radiation can be used for skin cancers,
- Gamma- ray emitting radioisotopes such as radioactive isotopes of radium, cobalt and other elements, can also be administered.
- methods of treatment of cancer with a compound of the invention are provided as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy has proven or can prove too toxic, e.g., results in unacceptable or unbearable side effects, for the subject being treated. Additionally, methods of treatment of cancer with a compound of the invention are provided as an alternative to surgery where the surgery has proven or can prove unacceptable or unbearable for the subject being treated.
- the compound of the invention can also be used in an in vitro or ex vivo fashion, such as for the treatment of certain cancers, including, bu no limited to leukemias and lymphomas, such treatment involving autologous stem cell transplants.
- This can involve a multi-step process in which the animal's autologous hematopoietic stem cells are harvested and purged of all cancer cells, the animal's remaining bone- marrow cell population is then eradicated via the administration of a high dose of a compound of the invention with or without accompanying high dose radiation therapy, and the stem cell graft is infused back into the animal. Supportive care is then provided while bone marrow function is restored and the animal recovers.
- Methods for treating cancer further include administering to a patient in need thereof an effective amount of a compound of the invention and another therapeutic agent tha is an anti-cancer agent.
- Suitable anticancer agents include, but are not limited to, methotrexate, taxol, L-asparaginase, mercaptopurme, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, topotecan, nitrogen mustards, Cytoxan, etoposide, 5 -fhioro racil, BCNU, irinotecan, camptothecins, bleomycin, doxorubicin, idarubicin, daunorubicin, actinomycin D, dactinomycin, piicamycin, mitoxantrone, aspara
- chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamicle; a!kyl sulfonates such as busulfan, treosulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including aitretamine, triethylenemelamine, trietylenephosphoramide, tiiethiyleiiethiophosphoramide and trimethyiolomelamine; TLK 286 (TELCYTATM); acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the alky
- eleutherobin paneratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mecbloretharaine, meehlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; triazines such as decarbazine; nitrosureas such as carmustine, ch iorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; epipodophyllins, such as etoposide, teniposide, topotecan, 9-aminocamptothecm, camptothecin orcrisnatoi; bisphosphonates, such as clodronate; antibiotics such as
- anthracyclin es such as annamycin, AD 32, alcarubicin, daunorubicin, dexrazoxane, DX-52-1, epirubicin, GPX-100, idarubicin, KRN5500, menogaril, dynemicin, including dynemicin A, an esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysiiis, actinomycin, authramycin, azaserine, bleomycins (e.g., A2 and B2), cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, detorubicin, 6 ⁇ diazo-5-oxo-L-norleucine, ADRIA
- Anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene, megastrol, droioxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and FARESTON® toremifene; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethirnide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestanie, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and AR1MIDEX® anastrozole; and anti-androgens such as flutamide,
- the compounds of the disclosure, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomers forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
- the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
- Optically active (+) and (-), (R)- and (S)-, or (D)- and (I.)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
- stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
- the present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecul es are nonsuperimposeable mirror images of one another.
- a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
- the present disclosure includes tautomers of any said compounds.
- compounds having the fol lowing structure (I) are provided:
- R. and R? are independently selected from the group consisting of: H and a saturated or unsaturated moiety having a linear, branched, or non-aromatic cyclic skeleton containing one to ten carbon atoms, and the carbon atoms are optionally substituted with: -OH, -I, -Br, -CI, -F, -CN, -C0 2 H, -CHO, -COSH, or -N0 2 ; or R 2 and Rs are fused and form a ring;
- R3 ⁇ 4 and R4 are independently selected from the group consisting of: H, R, ArR-, or R 3 and R 4 are joined to form a ring:
- R. 5 is selected from the group consisting of: H, R, ArR-, and Ar;
- Re is selected from the group consisting of: H, R, and ArR-;
- R 7 and Rg are independently selected from the group consisting of: H, R, and ArR-;
- R 10 is a linear, branched or cyclic, one to ten carbon saturated or unsaturated alkyl group;
- the ring formed by joining R 3 and R 4 is a three to seven member non- aromatic cyclic skeleton within the definition of R
- Y is defined as a moiety selected from the group consisting of: a linear, saturated or unsaturated, one to six carbon alkyl group, optionally substituted with R, ArR-— , or X; and,
- NRCOR I, Br, CI, F, CN, ( () ⁇ ! !.
- C0 2 R CHO, C R. CQNI3 ⁇ 4,— CONHR,— CON(R) 2 ,—COSH,— COSR,— N0 2 ,— S0 3 H,— SOR, and
- R-14 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryls, COR 24 , -CSR 24 ⁇ -OR 24 , and -NHR 24i wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH;
- Ar is an aromatic ring selected from the group consisting of: phenyl, naphthyl, anthracyl, pyrrolyl.
- R14 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, - COR 24 . -CSR 24 , -OR 24 , and -NHR 24 , wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH; R 1 5 is selected from the group consisting of optionally substituted alkyi, optionally substituted aikyianiino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- j f is selected from the group consisting of H and C 1-6 alkyi;
- Ri7 is selected from the group consisting of H and Q.e alkyi; R i8 and R30 are independently selected from the group consisting of H, C]_6 alkyi and -SH, with the proviso that Rig and R 30 cannot both be H;
- R39, R20, R21 and R-22 are independently H and Ci -6 alkyi, at least one of i 9 and R 20 is H; or R 20 and R 21 form a double bond, R19 is H, and
- R-22 is H or -6 alkyi
- R23 is selected from the group consisting of H and Cj_g alkyi; or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof.
- each optionally substituted alkyi, optionally substituted aikyianiino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl is, independently, optionally substituted with ( ).
- each R 24 is, independently, alkyi optionally substituted with halogen, -OH or -SH
- each optionally substituted aryl and optionally substituted heteroaryl is, independently, selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyi, optionally substituted anthracyl, optionally substituted phenanthryl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted thiophenyl, optionally substituted benzofuryl, optionally substituted benzothiophenyl, optionally substituted quinolinyl, optionally substituted isoquinoiinyl, optionally substituted imidazolyl, optionally substituted thiazoiyl, optionally substituted oxazolyl, and optionally substituted pyridinyl.
- 5 is selected from one of the following structures (II), (III), (IV), (V):
- Z is C(R 2 5) 2 , NR 25 , S, or O;
- each R25 is, independently, selected from the group consisting of H, - OH, -R 24 , -OR24, -O2CR24, -SH, -SR24, -SOCR74, -NH 2 , -N 3 , -NHR 24 , -N(R 24 )2, - NHCOR24, -NR24COR24, -R M ! '. -I, -Br, -CI, -F, -CN, -CO..1 1.
- each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH.
- R ! 5 is selected from the group consisting of:
- each R 25 is, independently, selected from the group consisting of H, -OH, ⁇ R,j. -OR7 4 , -0 2 CR 24 , -SI I -SR . -,. -8QCR 2 , -NH?, -N 3 , -NHR 24 , -N(R 24 ) 2 , - NHCOR24, -NR24COR24, - 24 H2, -I, -Br, -CI, -F, -CN, ⁇ ( 0>fS. - ⁇ ( ' ⁇ ). M .
- each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH.
- R15 is selected from the group consisting of
- R 5 is:
- Rie, R17, Ris, and R 30 are each methyl, In another further embodiment, R 16 is H, R 17 is methyl, i g is methyl, and 30 is methyl.
- any embodiment of the compounds of structure ( la ), as set forth above, and any specific substituent set forth herein for a R 14 , 15, R 16 , R 17 , Ris, Rig, R20 ⁇ d R 30 group in the compounds of structure (la), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (I) to form embodiments of the present disclosure not specifically set forth above.
- R.26 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cvcloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- 2 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cvcloalkyl, optionally substituted aryl, optionaiiy substituted heterocyclyl and optionally substituted heteroaryl;
- Ri6 is selected from the group consisting of H and Cj-e alkyl
- R 17 is selected from the group consisting of H and C
- i 8 is selected from the group consisting of and -SH, or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof.
- each optionally substituted alkyl, optionally substituted alkylamino, optionaiiy substituted cycloaikyi, optionaiiy substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl is, independently, optionally substituted with ().
- each R 28 is, independently, alkyl optionally substituted with halogen, -OH or -SH.
- each optionally substituted aryl and optionaiiy substituted heteroaryl is, independently, selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyi, optionally substituted anthracyl, optionaily substituted phenanthryl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted thiophenyl, optionally substituted benzofuryl, optionally substituted benzothiophenyl, optionally substituted quinolinyl, optionally substituted isoquinolmyl, optionally substituted imidazolyl, optionally substituted thiazolyl, optionally substituted oxazolyl, and optionally substituted pyridinyl.
- R 27 is selected from one of the following structures (II), (III), (IV), (V):
- Z is C(R-29)2, NR29, S, or O;
- each R29 is, independently, selected from the group consisting of H, OH, -OR ,,. -O2CR28, -SH, •• SR .,. -SOCR28, - H2, -N 3 , -NHR 28 , -Nf R K -NHCOR 28 , NR 28 COR 28 , -I, -Br, -CI, -F, ⁇ CN, -C0 2 e, -CO -CHO, -COR .,. -( ONI !,.
- CONHR 28 , -(OM R , K -COSH, -COSR28, -NO2, -SO3H, -SOR28 or -S0 2 R 2 8, wherein each R 28 is, independently, alkyl optionally substituted with halogen, -OH or -SH.
- R 27 is selected from the group consisting of
- R 17 and j 8 are each methyl.
- R 16 is H
- R 17 is methyl
- R 18 is it is understood that any embodiment of the compounds of structure (lb), as set forth above, and any specific substituent set forth herein for a R 25 , R 2 e, Rie, R 17 , Rig, Ris and R 20 group in the compounds of structure (lb), as set forth above, may be independently combmed with other embodiments and/or substituents of compounds of structure (I) to form embodiments of the present disclosure not specifically set forth above.
- R 20 in a particular embodiment, and/or claim, it is understood that each individual substituent may be deleted from the particular embodiment and/or claim and that the remaining list of substituents will be considered to be within the scope of the present disclosure.
- the invention provides a method of making a compound having structure (I), (la) or (lb).
- conjugate compositions having the following structure are provided:
- (T) is a targeting moiety
- (L) is an optional linker
- (D) is a compound having struture (I), (la) or (lb), below.
- (T) is an antibody.
- ADCs antibody-drug conjugates comprising compounds (D) having structure (I), (la) or (lb) are provided.
- Tj-(L)-(D) covalently link
- Any known method may be used to link the conjugate components.
- Any known linker technology may be used to link (T) to (D), Further, (T), (I.), and (D) may be modified in any suitable manner, as recognized by the artisan of reasonable skill, in order to facilitate conjugate formation.
- Targeting Moiety (T) The Targeting moiety (T) of the subject compositions includes within its scope any unit of a (T) that binds or reactively associates or complexes with a receptor, antigen or other receptive moiety associated with a given target-cell population.
- A. (T) is a molecule that binds to, complexes with, or reacts with a moiety of a ceil population sought to be targeted.
- the (T) acts to deliver the Drug (D) to the particular target cell population with which the (T) reacts.
- T include, but are not limited to, large molecular weight proteins such as, for example, full-length antibodies, antibody fragments, smaller molecular weight proteins, polypeptide or peptides, lectins, glycoproteins, non-peptides, vitamins, nutrient-transport molecules (such as, but not limited to, transferrin), or any other cell binding molecule or substance.
- large molecular weight proteins such as, for example, full-length antibodies, antibody fragments, smaller molecular weight proteins, polypeptide or peptides, lectins, glycoproteins, non-peptides, vitamins, nutrient-transport molecules (such as, but not limited to, transferrin), or any other cell binding molecule or substance.
- a (T) can form a bond to a Linker unit (I.) or a Drug (D).
- a (T) can form a bond to a (L) unit via a heteroatom of the (T).
- Heteroatoms that may be present on a (T) include sulfur (in one embodiment, from a sulfhydryl group of a (T)), oxygen (in one embodiment, from a carbonyl, carboxyi or hydroxyl group of a (T)) and nitrogen (in one embodiment, from a primary or secondary amino group of a (T)).
- These heteroatoms can be present on the (T) in the (T)'s natural state, for example a naturally-occurring antibody, or can be introduced into the (T) via chemical modification.
- a (T) has a sulfhydryl group and the (T) bonds to the
- the (T) has one or more lysine residues that can be chemically modified to introduce one or more sulfhydryl groups.
- Reagents that can be used to modify lysines include, but are not limited to, N-succinimidyl S- acetylthioacetate (SAT A) and 2 ⁇ Immothiol.ane hydrochloride (Traut's Reagent).
- the (L) can have one or more carbohydrate groups that can be chemically modified to have one or more sulfhydryl groups.
- the (T) bonds to the (L) via the sulfhydryl group's sulfur atom.
- the (T) can have one or more carbohydrate groups that can be oxidized to provide an aldehyde (-CHO) group (see, e.g., Laguzza et al, 1989, J. Med. Chem. 32(3):548-55).
- the corresponding aldehyde can form a bond with a reactive site on a portion of a (L).
- Reactive sites that can react with a carbonyl group on a (T) include, but are not limited to, hydrazine and hydroxylamine.
- Other protocols for the modification of proteins for the attachment or association of (D) are described in Coligati et al., Current Protocols in Protein Science, vol 2, John Wiley & Sons (2002), incorporated herein by reference.
- the (T) can include, for example a protein, polypeptide, or peptide include, but are not limited to, transferrin, epidermal growth factors ("EGF"), bombesin, gastrin, gastrin-releasing peptide, platelet-derived growth factor, IL-2, IL-6, transforming growth factor ("TG F"), such as TGF-a or TGF- ⁇ , vaccinia growth factor (“VGF”), insulin and insulin-like growth factors I and II, lectins and apoprotein from low density lipoprotein.
- EGF epidermal growth factors
- TG F transforming growth factor
- VGF vaccinia growth factor
- I and II lectins and apoprotein from low density lipoprotein.
- the (T) can also include an antibody, such as polyclonal antibodies or monoclonal antibodies.
- the antibody can be directed to a particular antigenic determinant, including for example, a cancer cell antigen, a viral antigen, a microbial antigen, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments thereof.
- Methods of producing polyclonal antibodies are known in the art.
- a monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art.
- Selected Lymphocyte Antibody Method (SLAM) (Babcook, J.S., et ai, A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A, 1996.
- the monoclonal antibody can be, for example, a human monoclonal antibody, a humanized monoclonal antibody, an antibody fragment, or a chimeric antibody (e.g., a human-mouse antibody).
- Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; and Olsson et al., 1982, Meth. Enzymol. 92:3-16). See also, Huse et al., 1989, Science 246: 1275-1281 and McLean et al. J Immunol. 2005 Apr 15;174(8):4768-78.
- the antibody can also be a bispecific antibody.
- Methods for making bispeciiic antibodies are known in the art. Traditional production of full-length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain- light chain pairs, where the two chains have different specificities (see, e.g., Milstein et a!., 1983, Nature 305:537-539; International Publication No. WO 93/08829, Traunecker et al, 1991, EMBO J. 10:3655-3659.
- antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences.
- the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, a d CH 3 regions. It is preferred to have the first heavy-chain constant region (C HI ) containing the site necessary for light chain binding, present in at least one of the fusions.
- Nucleic acids with sequences encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
- the bispecific antibodies can have a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm.
- This asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation (International Publication No. WO 94/04690) which is incorporated herein by reference in its entirety.
- bispecific antibodies can be prepared for use in the treatment or prevention of disease as defined herein.
- hybrid or bifunctional antibodies can be derived either biologically, i.e., by cell fusion techniques, or chemically, especially with cross-linking agents or disulfi de-bridge forming reagents, and may comprise whole antibodies or fragments thereof. Methods for obtaining such hybrid antibodies are disclosed for example, in International Publication WO 83/03679, and European Patent Publication No. EPA 0 217 577, both of which are incorporated herein by reference.
- the antibody also can be a functionally active fragment, derivative or analog of an antibody that immunospecifiealr binds to a target antigen (e.g., a cancer antigen, a viral antigen, a microbial antigen, or other antibodies bound to cells or matrix).
- a target antigen e.g., a cancer antigen, a viral antigen, a microbial antigen, or other antibodies bound to cells or matrix.
- a target antigen e.g., a cancer antigen, a viral antigen, a microbial antigen, or other antibodies bound to cells or matrix.
- a target antigen e.g., a cancer antigen, a viral antigen, a microbial antigen, or other antibodies bound to cells or matrix.
- “functionally active” means that the fragment, derivative or analog is able to recognize the same antigen that the antibody from which the fragment, derivative or analog is derived recognized.
- the antigenicity of the idiotype of the immunoglobulin molecule
- synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art (e.g., the BIA core assay) (see, e.g., Kabat et ah, 1991 , Sequences of Proteins of immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md.; Kabat et al, 1980, J. Immunology 125(3):961 -969).
- antibodies include fragments of antibodies such as, but not limited to, F(ab') 2 fragments.
- SCAs single chain antibodies
- Recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, also can be used.
- Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule.
- CDRs complementarity determining regions
- Chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Publication No. WO 87/02671 ; European Patent Publication No. 0 184 187; European Patent Publication No. 0 171 496; European Patent Publication No. 0 173 494; International Publication No, WO 86/01533; U.S. Pat. No, 4,816,567; European Patent Publication No. 012 023; Berter et al, 1988, Science 240: 1041-1043; Liu et al, 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987, J.
- Human antibodies can be prepared, for example, using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes.
- the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all. or a portion of a polypeptide of the invention.
- Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology.
- the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B ceil differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies.
- Human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection.”
- a selected non-human monoclonal antibody e.g., a mouse antibody
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter, 1991 , J. Mol. Biol. 227:381 ; Marks et al, 1991, J. Mol. Biol.
- the antibody is a fusion protein of an antibody, or a functionally active fragment thereof.
- an antibody can be fused via a covalent bond (e.g., a peptide bond) at either the N-termimis or the C-termmus to an amino acid sequence of another protein (or portion thereof, such as at least a 10, 20 or 50 amino acid portion of the protein) that is not the antibody.
- Antibodies also include analogs and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retain its antigen binding immunospecificity.
- the derivatives and analogs of the antibodies include those that have been further modified, e.g., by glycosylation, acetylation, pegyiation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular antibody unit or other protein, etc.
- analog or derivative can contain one or more unnatural amino acids.
- the antibodies can have modifications (e.g., substitutions, deletions or additions) in amino acid residues that interact with Fc receptors.
- antibodies include antibodies having modifications in amino acid residues identified as involved in the interaction between the anti-Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97/34631, which is incorporated herein by reference in its entirety).
- Antibodies immunospecific for a target antigen can be obtained commercially or other source or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques.
- the nucleotide sequence encoding antibodies immunospecific for a cancer cell antigen can be obtained, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.
- antibodies available for the treatment of cancer include, but are not limited to, humanized anti HER2 monoclonal antibody, HERCEPTIN® (trastuzumab; Genentech); RITUXAN® (rituximab; Genentech) which is a chimeric anti CD20 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma; OvaRex (AltaRex Corporation, MA) which is a murine antibody for the treatment of ovarian cancer; Panorex (Glaxo Wellcome, NC) which is a murine IgG2a antibody for the treatment of colorectal cancer; Cetuximab Erbitux (Imclone Systems Inc., NY) which is an anti-EGF IgG chimeric antibody for the treatment of epidermal growth factor positive cancers, such as head and neck cancer; Vitaxin (Medlmmune, Inc., MD) which is a humanized antibody for the treatment of sarcoma; Campath I/H
- antibodies useful in the treatment of cancer include, but are not limited to, antibodies against the following antigens (exemplary cancers are indicated in parentheses): CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y (carcinomas), Lewis X (carcinomas), alpha fetoprotein (carcinomas), CA 242 (colorectal), placental alkaline phosphatase (carcinomas), prostate specific membrane antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinomas), MAGE-1 (carcinomas), MAGE-2 (carcinomas), MAGE-3 (carcinomas), MAGE-4 (carcinomas), anti transferrin receptor (carcinomas), p97 (melanoma), MUCl -KXH (breast cancer), CEA (colorectal), gplOO (melanoma), MARTI (melanoma), prostate specific antigen (PSA) (prostate), IL-2
- Some specific, useful antibodies include, but are not limited to, BR96 mAb (Trail et al., 1993, Science 261 :212-215), BR64 (Trail et al, 1997, Cancer Research 57:100-105), raAbs against the CD40 antigen, such as S2C6 mAb (Francisco et al., 2000, Cancer Res.
- the antibody also can be an antibody that binds to an antigen that is present on a target cell or target cell population.
- transmembrane polypeptides and other markers can be specifical ly expressed on the surface of one or more particular type(s) of target cells (e.g., a cancer cell) as compared to on one or more normal (e.g., a non-cancerous cell(s)).
- target cells e.g., a cancer cell
- normal e.g., a non-cancerous cell(s)
- the antibodies include, but are not limited to, antibodies against tumor-associated antigens (TAA).
- TAA tumor-associated antigens
- Such tumor-associated antigens are known in the art, and can prepared for use in generating antibodies using methods and information which are well known in the art.
- compositions optionally further include a Linker moiety (L).
- L is a Afunctional compound which can be used to link a (D) and a (T) to form a conjugate composition, T-L-D.
- conjugates allow the selective delivery of drags to target cells (e.g., tumor cells).
- (L)s include a divalent substituent such as an alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: — (CR 2 ) J1 0(CR2) n — , repeating units of alkyloxy (e.g., polyethylenoxy, PEG, poiymethyleneoxy) and alkylamino (e.g., polyethyienearnino, jeffamineTM); and diacid ester and amides including succinate, suecinamide, diglycoiate, malonate, and caproamide.
- alkyldiyl e.g., polyethylenoxy, PEG, poiymethyleneoxy
- alkylamino e.g., polyethyienearnino, jeffamineTM
- diacid ester and amides including succinate, suecinamide, diglycoiate, malonate, and capro
- the subject compositions can be prepared using a (L) unit having a reactive site for binding to the (D) and (T).
- (L) has a reactive site which has an electrophilic group that is reactive to a nucleophilic group present on (T).
- Useful nucleophilic groups on (T) include but are not limited to suifhydryl, hydroxy! and amino groups.
- the heteroatom of the nucleophilic group of (T) is reactive to an electrophilic group on (L) and forms a covale t bond to (L).
- Useful electrophilic groups include, but are not limited to maleimide and haloacetamide groups.
- the nucleophilic group on (T) provides a convenient site for attachment to (L).
- (L) has a reactive site which has a nucleophilic group that is reactive to an electrophilic group present on (T).
- Useful electrophilic groups on (T) include, but are not limited to, aldehyde and ketone carbonyl groups.
- the heteroatom of a nucleophilic group of (L) can react with an electrophilic group on (T) and form a covalent bond to (T).
- Useful nucleophilic groups on (L) include, but are not limited to, hydrazide, oxirne, amino, hydrazine, thiosemicarbazone, hydrazine carboxyiate, and arylhydrazide.
- the electrophilic group on (T) provides a convenient- site for attachment to (L).
- Carboxylic acid functional groups and chloroformate functional groups are also useful reactive sites for (L) because they can react with amino groups of a (D) to form an amide linkage.
- a carbonate functional group on (L) such as but not limited to p-nitrophenyl carbonate, which can react with an amino group of a (D) to form a carbamate linkage.
- (L) comprises a linker moiety disclosed in WO 2012/1 13847.
- (L) comprises a linker moiety disclosed in U.S. 8,288,352.
- (L) comprises a linker moiety disclosed in U.S. 5,028,697.
- (L) comprises a linker moiety disclosed in U.S. 5,006,652.
- (L) comprises a linker moiety disclosed in U.S. 5,094,849.
- (L) comprises a linker moiety disclosed in U.S. 5,053,394. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,122,368. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,387,578. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,547,667. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,622,929. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,708,146. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 6,468,522.
- (L) comprises a linker moiety disclosed in U.S. 6,103,236. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 6,638,509. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 6,214,345. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 6,759,509. In another embodiment, (L) comprises a linker moiety disclosed in WO 2007/103288. In another embodiment, (L) comprises a linker moiety disclosed in WO 2008/083312. In another embodiment, (I.) comprises a linker moiety disclosed in WO 2003/068144.
- (L) comprises a linker moiety disclosed in WO 2004/016801. In another embodiment, (L) comprises a linker moiety disclosed in WO 2009/134976. In another embodiment, (L) comprises a linker moiety disclosed in WO 2009/134952. In another embodiment, (L) comprises a linker moiety disclosed in WO 2009/134977. In another embodiment, (L) comprises a linker moiety disclosed in W 2002/08180. In another embodiment, (L) comprises a linker moiety disclosed in WO 2004/043493. In another embodiment, (L) comprises a linker moiety disclosed in WO 2007/018431. In another embodiment, (L) comprises a linker moiety disclosed in WO 2003/026577.
- (L) comprises a linker moiety disclosed in WO 2005/077090. in another embodiment, (I.) comprises a linker moiety disclosed in WO 2005/082023. In another embodiment, (L) comprises a linker moiety disclosed in WO 2007/01 1968. In another embodiment, (L) comprises a linker moiety disclosed in WO 2007/038658. In another embodiment, (L) comprises a linker moiety disclosed in WO 2007/059404. In another embodiment, (L) comprises a linker moiety disclosed in WO 2006/110476. in another embodiment, (I.) comprises a linker moiety disclosed in WO 2005/112919. In another embodiment, (L) comprises a linker moiety disclosed in WO 2008/103693.
- (L) comprises a linker moiety disclosed in U.S. 6,756,037. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 7,087,229. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 7,122,189. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 7,332,164. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,556,623. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,643,573. In another embodiment, (L) comprises a linker moiety disclosed in U.S. 5,665,358.
- Linkers (L) comprising a self-immo!ative component may also be used.
- L linkers
- An example of a seif-immolative component is p-aminobeiizylcarbamoyl (PABC).
- linkers may be used in the invention.
- the commercially available cieavable linker sulfosuccimmidyl. 6 ⁇ [3 ' (2- pyridyldithio)-propionamido] hexanoate sulfo-LC-SPDP: Thermo Pierce Cat# 21650
- Non-cieavable linker succmi.rnid.yi 4-[N-maleimidomethyl]cyclohexane-l ⁇ carboxyiate (SMCC: Thermo Pierce Cat# 22360) may be used, as demonstrated herein.
- (D) is a compound having the structure ( 1), (la) or (lb) as described herein. It will be recognized by the artisan of reasonable skill that compounds of structure (I), (Ia) or (lb) may be appropriately modified to facilitate a conjugation reaction with (L), or if (L) is not present, with (T), and formation of a conjugate (T)- (L)-(D) or (T)-(D). Any point of attachment on (D) may be used.
- the C -terminus of (D) forms the point of attachment in a (T)-(L)-(D) conjugate.
- the N-terminus of (D) forms the point of attachment in a (T)-(L)- (D) conjugate.
- a side chain of (D) forms the point of attachment in a (T)-(L)-(D) conjugate,
- Novel Conjugates Comprising Microtubule Disrupting Peptide Toxins
- conjugates comprising microtubule disrupting peptide toxins covalently linked in the conjugate through the side chain of the N-terminal amino acid are provided.
- the microtubule disrupting peptide toxin is hemiasterlm or an analog thereof and the toxin is covalently linked in the conjugate through the indole moiety within the side chain of the N-terminal amino acid of the toxin peptide.
- the microtubule disrupting peptide toxin is HTI-286 or an analog thereof and the toxin is covalently linked in the conjugate through the phenyl group within the side chain of the -terminal amino acid of the toxin peptide.
- the microtubule disrupting peptide toxin is a compound having structure (I), (Ia) or (lb) as disclosed herein.
- compositions have anti-mi totic activity and the following structure:
- (VII) wherein (T) is a targeting moiety as described herein, (L) is an optional linker as described herein, and (PT) is a microtubule disrupting peptide toxin that covalently linked to (L) through the side chain of the N-terminal amino acid of (PT), or if (I.) is not present, (PT) is covalently linked to (T) through the side chain of the N- terminal amino acid of (PT).
- (T) is an antibody.
- ADCs antibody-drug conjugates
- (T)-(L)-(PT) has the following structure:
- Rj and R2 are independently selected from the group consisting of: H and a saturated or unsaturated moiety having a linear, branched, or non-aromatic cyclic sskeleton containing one to ten carbon atoms, and the carbon atoms are optionally substituted with: -OH, -I, -Br, -CI, -F, -CN, -C0 2 H, -CHO, -COSH, or -NO?;
- R and R 4 are independently selected from the group consisting of: H, R, ArR-, or R 3 and R are joined to form a ring;
- R 3 j is selected from the group consisting of: H, R', ArR-, Ar-R-Ar, R- Ar-Ar, Ar-Ar-R-, and Ar, wherein each R and each Ar may be substituted, and zero to ten heteroatoms may replace carbon atoms in the chain, for example O or S or N may be incorporated into the carbon chain; in one embodiment, wherein R' is wherein m is an integer from one to fifteen;
- Re is selected from the group consisting of: H, R, and ArR-; R 7 and Rg are independently selected from the group consisting of: H R, and ArR-; and
- R32 is selected from:
- Z is defined as a moiety selected from the group consisting of: -OH, - OR; -SH; -8R; -N3 ⁇ 4; - RCH(R )COOH; and -NHCH(R 1 -.)COOH, wherein R n is a moiety having the formula: R, or -4 and R. 12 and R 13 are independently selected from the group consisting of: H; R; and -C(NH)(NH 2 ),
- Y is defined as a moiety selected from the group consisting of: a linear, saturated or unsaturated, one to six carbon alkyl group, optionally substituted with R, Ar — , or X; and,
- X is defined as a moiety selected from the group consisting of: OH,
- CONH2 — CONHR,— CON(R) 2 ,—COSH,— COSR,—NO?, SO .! ! .— SOR, and — S0 2 R;
- i 4 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloaikyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryls, COR 2 4, -CSR 24, -OR 24I and -NHR 24i wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH,
- the ring formed by joining R 3 and R4 is a three to seven member non- aromatic cyclic skeleton within the definition of R,
- Y is defined as a moiety selected from the group consistmg of: a linear, saturated or unsaturated, one to six carbon alkyl group, optionally substituted with R, ArR-— , or X; and,
- Ar is an aromatic ring selected from the group consisting of: phenyl, naphthyi, anthracyl, pyrrolyl.
- R 32 is:
- R ? is: o o
- (T)-(L)-(PT) has the following structure:
- Ri 5 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- Rj 6 is selected from the group consisting of H and C 1-6 alkyl
- Ri 7 is selected from the group consisting of H and C 1-6 alkyl
- Rig and R 30 are independently selected from the group consisting of H,
- R 32 is selected from:
- Z is defined as a moiety selected from the group consisting of: -OH, -
- the ring formed by joining R. 3 and R4 is a three to seven member non- aromatic cyclic skeleton within the definition of R,
- Y is defined as a moiety selected from the group consisting of: a linear, saturated or unsaturated, one to six carbon alkyl group, optionally substituted with R, ArR-— , or X; and,
- CONH2 — CONHR,— CON(R) 2 ,—COSH,— COSR,—NO?, SO .! !.— SOR, and or a stereoisomer, prodrug or pharmaceut cally acceptable salt thereof.
- (T)-(L)-(PT) has the following structure:
- -15 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- Ri 6 is selected from the group consisting of H and Ci assignment 6 alkyl
- R37 is selected from the group consisting of H and C 1-6 alkyl
- j g and R30 are independently selected from the group consisting of H,
- Ci-6 alkyl and -SH with the proviso that both the Rig and R 30 substituents cannot be H;
- the ring formed by joining R3 ⁇ 4 and 4 is a three to seven member non- aromatic cyclic skeleton within the definition of R,
- Y is defined as a moiety selected from the group consisting of: a linear, saturated or imsaturated, one to six carbon alkyl group, optionally substituted with R, ArR , or X; and,
- (T)-(L)-(PT) has the following structure:
- Ri is selected from the group consisting of optionally substituted alkyl, optionally substituted aikyianiino, optionally substituted cycloalkyl, optionally substituted aryi, optionally substituted heterocyclyl, optionally substituted heteroaiyl, - COR24, -CSR 24 , -OR24, -SR24, and -NHR 24( wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH;
- Ri5 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- R] 6 is selected from the group consisting of H and C 1-6 alkyl
- R 17 is selected from the group consisting of H and Q.e alkyl
- Rig and R30 are independently selected from the group consisting of H, C] _6 alkyl and -SH, with the proviso that both the Ris and R30 substituents cannot be H;
- (T)-(L)-(PT) has the following structure:
- R 14 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaiyl, - COR24, -CSR 24 , -OR 24 , -SR24, and -NHR24, wherein each R 24 is, independently, alkyl optionally substituted with halogen, -OH or -SH;
- Ri5 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaiyl;
- R] 6 is selected from the group consisting of H and C 1-6 alkyl
- R 17 is selected from the group consisting of H and Q.e alkyl
- R i8 and R30 are independently selected from the group consisting of H, C] _6 alkyl and -SH, with the proviso that both the Ris and R30 substituents cannot be H;
- (T)-(L)-(PT) has the following structure:
- R] 5 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
- (T)-(L)-(PT) has the following structure:
- (T) ⁇ (L) ⁇ (PT) has the following structure:
- (PT) is a hemisterlin analog, such as those disclosed in US 7,579,323, which is hereby incorporated by reference in its entirety for all purposes.
- ADCs comprising microtubule disrupting peptide toxins
- peptide linkage through the side chain of the N-terminal amino acid holds several advantages.
- the side chains of such peptide toxins are ammenable to chemical modifications and manipulations that facilitate formation of covalently linked conjugates without compromising potency.
- such conjugates are potent cytotoxic compositions capable of delivering peptide toxin payloads.
- compositions of the present disclosure comprise a compound of structure (I), (la) or (lb) and a pharmaceutically acceptable carrier, diluent or excipient.
- the compound of stracture (I), (la) or (lb) is present in the composition in an amount which is effective to treat a particular disease or condition of interest - e.g., in an amount sufficient to treat cancer or tumour ceil growth, and preferably with acceptable toxicity to the patient.
- the activity of compounds of structure (I), (la) or (lb) can be determined by one skilled in the art, for example, as described in the Examples below. Appropriate concentrations and dosages can be readily determined by one skilled in the art,
- compositions of the disclosure can be prepared by combining a compound of the disclosure with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
- compositions of the disclosure are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
- Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the disclosure in aerosol form may hold a plurality of dosage units.
- composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this disclosure.
- a pharmaceutical composition of the disclosure may be in the form of a solid or liquid.
- the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form.
- the carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
- compositions of the present disclosure typically are either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
- the pharmaceutical compositions may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
- a solid composition will typically contain one or more inert diluents or edible carriers.
- binders such as earboxyrnethylceUulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
- excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like
- lubricants such as magnesium stearate or Sterotex
- glidants such as colloidal silicon dioxide
- sweetening agents such as sucrose or saccharin
- a flavoring agent
- the pharmaceutical composition when in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil
- compositions of the disclosure may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension.
- the liquid may be for oral administration or for delivery by injection, as two examples.
- pharmaceutical compositions of the disclosure typically contain, in addition to the present compoimds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
- a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
- Liquid pharmaceutical compositions of the disclosure may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Physiological saline is a preferred adjuvant
- a liquid pharmaceutical composition of the disclosure intended for either parenteral or oral administration should contain an amount of a compound of the disclosure such that a suitable dosage will be obtained.
- compositions of the disclosure may be intended for topical administration, in which case the earner may suitably comprise a solution, emulsion, ointment or gel base.
- the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
- Thickening agents may be present in a pharmaceutical composition for topical administration.
- the composition may include a transdermal patch or iontophoresis device.
- compositions of the disclosure may be intended for rectal administration, in the form, for example, of a suppositoiy, which will melt in the rectum and release the drug.
- Compositions for rectal administration may contain an oleaginous base as a suitable nonirritating excipient.
- bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
- compositions of the disclosure may include various materials, which modify the physical form of a solid or liquid dosage unit.
- the composition may include materials that form a coating shell around the active ingredients.
- the materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents.
- the active ingredients may be encased in a gelatin capsule.
- compositions of the disclosure may be prepared in dosage units that can be administered as an aerosol.
- aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the disclosure may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontamers, and the like, which together may form a kit. One skilled in the art, without undue experimentation may determine preferred aerosols.
- compositions of the disclosure may be prepared by methodology well known in the pharmaceutical art.
- a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the disclosure with sterile, distilled water so as to form a solution.
- a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
- Surfactants are compounds that non-covalentiy interact with the compound of the disclosure so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
- the compounds of the disclosure, or their pharmaceutically acceptable salts are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
- Compounds of the disclosure, or pharmaceutically acceptable derivatives thereof, may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents.
- Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the disclosure and one or more additional active agents, as well as administration of the compound of the disclosure and each active agent in its own separate pharmaceutical dosage formulation.
- a compound of the disclosure and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations.
- the compounds of the disclosure and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.
- suitable protecting groups include hydroxy, amino, mercapto and carboxylie acid.
- suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyi (for example, t-butyldimethylsilyl, t- btttyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like
- suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxyearbonyl, and the like.
- Suitable protecting groups for mercapto include -C(0) ⁇ R" (where R" is alkyl, aryl or arylalkyl), nethoxybenzyl, trityl and the like.
- Suitable protecting groups for carboxylie acid include alkyl, aryl or arylalkyl esters.
- Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.
- the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
- compounds of the disclosure which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art.
- Salts of the compounds of the disclosure can be converted to their free base or acid form by standard techniques.
- the vinylogous amino ester was deprotected and coupled to Boc-t- leucine according to procedures described by Nieman J. A. et al. J. Nat. Prod. 2003, 66, 183-- 199 with no modifications.
- the mixture was transferred to a separatory funnel and the organic phase was washed with brine, dried over MgS04, filtered and concentrated to give the desired suifonyl chloride.
- the thusly derived chloride was subsequently dissolved in THF and added dropwise to a stirred aqueous solution of concentrated ammonium hydroxide at 0°C.
- the reaction was concentrated under reduced pressure and diluted with w r ater and ethyl acetate.
- the organic phase was washed with brine, dried over MgSG 4 , filtered and concentrated to give the desired sulfonamide in sufficient purity for further use.
- the above solid was added to a round bottom flask equipped with a stir bar.
- Phosphorous pentachloride (3.22g, 1.3 equiv) was added in a single charge and the flask was gently shaken to mix the solids. A gas was observed to form and the solids became slightly molten. A singular drop of water was added to the mixture and a vigorous evolution of gas was observed, with more significant melting of the reaction mixture.
- the flask was submerged in an oil bath at 70°C and the molten mixture manipulated to attempt to make it as uniform as possible.
- Example 4 was synthesized from Examples 2 and 3 according to General Procedures 2 and 7 with the inclusion of tri-isoproypsilane (2equiv) to Procedure 9.
- Example 3 Title compound was prepared from Example 3 and rneihanesulfonamide using General Procedures 2 and 7.
- Example 3 Title compound was prepared from Example 3 and 2- nitro phenyl sulfonamide using General Procedures 2 and 7.
- 2-fluorobenzylsulfamamide was prepared from 2-fluorobenzylamine accordmg to General Procedure 14; the title compound was prepared from Example 3 and 2-fiuorobenzyIsulfamamide using General Procedures 2 and 7.
- Piperidine-1 -sulfonamide was synthesized from piperidine according to
- Example 3 Title compound was prepared from Example 3 and hexane- sulfonamide using General Procedures 2 and 7.
- Example 36 was prepared from Example 36 and (S,E)-4-((S)-2- amino-N, 3 ,3 -trimethy ibutanamido)-N-(benzy isulfonyl)-2, 5 -dimethylhex-2-enamide using General Procedures 3, 4 and 7.
- the aqueous phase was washed twice with ethyl acetate (5mL) and the organic phases were combined, washed with brine, dried over MgS0 4 , filtered and concentrated.
- the reaction product was purified by silica gel chromatography (5-15% MeOH in ( ⁇ ! .( ⁇ ⁇ . ) to afford the Boc protected intermediate as a colouless glass (0.027g, 66%).
- the intermediaie was deprotected according to General Procedure 7 to give the title compound.
- Example 3 Title compound was prepared from Example 3 and pyridin-3- ylmethanesulfonamide using General Procedures 2 and 7,
- Example 3 Title compound was prepared from Example 3 and methyl 4- sulfamoylbenzoate using General Procedures 2, 3 and 7.
- Example 3 Title compound was prepared from Example 3 and pyridme-3- sulfonamide using General Procedures 2, and 7.
- Tritylmercaptan (1.48 g, 5.36 miiiol, 1.05 eq) in THF (5 mL) was added dropwi.se to a stirred suspension of sodium hydride (60% dispersion in mineral oil, 214 mg, 5.36 mmol, 1.05 eq) in THF (5 mL) under N? at 0°C.
- 4- (bromomethyl)benzonitrile (l .OOg, 5.10 mmol, 1.0 eq) in THF (5 mL) was added and the reaction was allowed to come to rt. After 1 h, TLC indicated complete conversion of starting material. The reaction was quenched by adding saturated ammonium chloride, then some dH 2 0.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015023415-1A BR112015023415B1 (en) | 2013-03-15 | 2014-03-14 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, COMPOSITION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
JP2016503104A JP6431038B2 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and antimitotic compounds and methods of use |
KR1020157029402A KR102178606B1 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
ES14763699T ES2741207T3 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and antimitotic compounds, and methods of use thereof |
CN201480027374.0A CN105358174B (en) | 2013-03-15 | 2014-03-14 | Have cytotoxicity and antimitotic compound and its application method |
EP19174765.8A EP3590922A1 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
NZ71198214A NZ711982A (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
PL14763699T PL2968440T3 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
MYPI2015002339A MY174813A (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US14/776,654 US10201614B2 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
CA2906784A CA2906784C (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
SG11201507619PA SG11201507619PA (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EA201591632A EA029818B8 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds and methods of using the same |
MX2015012868A MX368258B (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same. |
AU2014228489A AU2014228489B2 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP14763699.7A EP2968440B1 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
DK14763699.7T DK2968440T3 (en) | 2013-03-15 | 2014-03-14 | CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHODS OF USE THEREOF |
CN201910125160.1A CN110143999B (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and antimitotic compounds and methods of use thereof |
IL24152415A IL241524B (en) | 2013-03-15 | 2015-09-10 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
ZA2015/06918A ZA201506918B (en) | 2013-03-15 | 2015-09-17 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
HK16108315.3A HK1220140A1 (en) | 2013-03-15 | 2016-07-15 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
HK16108733.7A HK1220626A1 (en) | 2013-03-15 | 2016-07-21 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US16/273,045 US11617777B2 (en) | 2013-03-15 | 2019-02-11 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US18/112,402 US20230390354A1 (en) | 2013-03-15 | 2023-02-21 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792066P | 2013-03-15 | 2013-03-15 | |
US201361792020P | 2013-03-15 | 2013-03-15 | |
US61/792,066 | 2013-03-15 | ||
US61/792,020 | 2013-03-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/776,654 A-371-Of-International US10201614B2 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US16/273,045 Continuation US11617777B2 (en) | 2013-03-15 | 2019-02-11 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014144871A1 true WO2014144871A1 (en) | 2014-09-18 |
Family
ID=51537820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/029463 WO2014144871A1 (en) | 2013-03-15 | 2014-03-14 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
Country Status (21)
Country | Link |
---|---|
US (4) | US9522876B2 (en) |
EP (2) | EP2968440B1 (en) |
JP (1) | JP6431038B2 (en) |
KR (1) | KR102178606B1 (en) |
CN (2) | CN105358174B (en) |
AU (1) | AU2014228489B2 (en) |
CA (1) | CA2906784C (en) |
DK (1) | DK2968440T3 (en) |
EA (1) | EA029818B8 (en) |
ES (1) | ES2741207T3 (en) |
HK (2) | HK1220140A1 (en) |
IL (1) | IL241524B (en) |
MX (1) | MX368258B (en) |
MY (1) | MY174813A (en) |
NZ (1) | NZ711982A (en) |
PL (1) | PL2968440T3 (en) |
PT (1) | PT2968440T (en) |
SG (1) | SG11201507619PA (en) |
TR (1) | TR201911139T4 (en) |
WO (1) | WO2014144871A1 (en) |
ZA (1) | ZA201506918B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
WO2016053107A1 (en) * | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
JP2017197512A (en) * | 2016-02-08 | 2017-11-02 | シンアフィックス ビー.ブイ. | Novel antibody-conjugates with improved therapeutic index for targeting cd30 tumors and methods for improving therapeutic index of antibody-conjugates |
JP2017200902A (en) * | 2016-02-08 | 2017-11-09 | シンアフィックス ビー.ブイ. | Novel antibody-conjugate with improved therapeutic index for targeting HER2 tumor and method for improving therapeutic index of antibody-conjugate |
US9840481B2 (en) | 2016-03-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Allosteric modulators of nicotinic acetylcholine receptors |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9986733B2 (en) | 2015-10-14 | 2018-06-05 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2019031614A1 (en) | 2017-08-10 | 2019-02-14 | 大日本住友製薬株式会社 | Antibody-drug conjugates including hemiasterlin derivative |
WO2019031615A1 (en) | 2017-08-10 | 2019-02-14 | 大日本住友製薬株式会社 | Hemiasterlin derivatives and antibody-drug conjugates including same |
US10322192B2 (en) | 2016-03-02 | 2019-06-18 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
RU2695787C1 (en) * | 2018-11-07 | 2019-07-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Use of the compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol for treating her2-positive tumors experimentally |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
WO2020166600A1 (en) | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | Hemiasterlin derivative having cysteine residue |
JP2021063124A (en) * | 2014-09-25 | 2021-04-22 | アンティコア バイオファーマ リミテッド | Biological materials and uses thereof |
US11603396B2 (en) | 2019-05-22 | 2023-03-14 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11679120B2 (en) | 2019-12-04 | 2023-06-20 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11845950B2 (en) | 2018-06-06 | 2023-12-19 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015374118B2 (en) | 2014-12-29 | 2020-07-23 | The Trustees Of The University Of Pennsylvania | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
EP3892305A1 (en) * | 2015-01-30 | 2021-10-13 | Sutro Biopharma, Inc. | Hemiasterlin derivatives for conjugation and therapy |
WO2018187563A1 (en) | 2017-04-06 | 2018-10-11 | Nissan Chemical America Corporation | Hydrocarbon formation treatment micellar solutions |
JP2021006595A (en) | 2017-09-13 | 2021-01-21 | 日産化学株式会社 | Crude oil recovery chemical |
MX2020004470A (en) | 2017-11-03 | 2020-09-03 | Nissan Chemical America Corp | Using brine resistant silicon dioxide nanoparticle dispersions to improve oil recovery. |
WO2020166592A1 (en) * | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | Hemiasterlin derivative and antibody-drug conjugate thereof |
Citations (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012023A1 (en) | 1978-12-05 | 1980-06-11 | Claude Peter Windsor-Smith | Change speed gear |
WO1983003679A1 (en) | 1982-04-12 | 1983-10-27 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
EP0171496A2 (en) | 1984-08-15 | 1986-02-19 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
EP0184187A2 (en) | 1984-12-04 | 1986-06-11 | Teijin Limited | Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric DNA encoding it |
EP0217577A2 (en) | 1985-09-12 | 1987-04-08 | Hybritech Incorporated | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5006652A (en) | 1988-08-08 | 1991-04-09 | Eli Lilly And Company | Intermediates for antibody-vinca drug conjugates |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5094849A (en) | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
US5122368A (en) | 1988-02-11 | 1992-06-16 | Bristol-Myers Squibb Company | Anthracycline conjugates having a novel linker and methods for their production |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5387578A (en) | 1990-08-03 | 1995-02-07 | Farmitalia Carlo Erba S.R.L. | New linker for bioactive agents |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
WO1996033211A1 (en) | 1995-04-20 | 1996-10-24 | University Of British Columbia | Biologically active peptides and compositions, their use |
US5569825A (en) | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6103236A (en) | 1995-05-10 | 2000-08-15 | Kyowa Hakko Kogyo Co., Ltd. | Toxin conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO2002008180A1 (en) | 2000-07-24 | 2002-01-31 | Matsushita Electric Industrial Co., Ltd. | Bis(4-mercaptophenyl) sulfide derivatives, process for the preparation thereof and electronic components |
US6468522B1 (en) | 1999-07-22 | 2002-10-22 | University Of Medicine And Dentistry Of New Jersey | Controlled release of thioamide moiety-containing therapeutic agents |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
WO2003068144A2 (en) | 2001-12-21 | 2003-08-21 | Immunogen, Inc. | Cytotoxic agents |
WO2004016801A2 (en) | 2002-08-16 | 2004-02-26 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
WO2004026293A2 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO2005077090A2 (en) | 2004-02-05 | 2005-08-25 | Seattle Genetics, Inc. | Improved methods of producing antibody conjugates |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2006110476A2 (en) | 2005-04-08 | 2006-10-19 | Medarex, Inc. | Cytotoxic compounds and conjugates comprising duocarmycins with cleavable substrates |
WO2007011968A2 (en) | 2005-07-18 | 2007-01-25 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
WO2007038658A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
WO2008083312A2 (en) | 2006-12-28 | 2008-07-10 | Medarex, Inc. | Chemical linkers and cleavable substrates and conjugates thereof |
WO2008103693A2 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
US20080305044A1 (en) * | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
US7528152B2 (en) * | 2002-03-22 | 2009-05-05 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof in the treatment of cancer |
US7579323B1 (en) | 1997-12-19 | 2009-08-25 | The University Of British Columbia | Hemiasterlin analogs |
WO2009134976A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
WO2009134977A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Cross-linkers and their uses |
WO2009157771A2 (en) | 2008-06-27 | 2009-12-30 | Merus B.V. | Antibody producing non-human mammals |
WO2010001251A2 (en) | 2008-07-02 | 2010-01-07 | Argen-X B.V. | Antigen binding polypeptides |
WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
EP2326349A1 (en) | 2008-07-21 | 2011-06-01 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
WO2012116453A1 (en) | 2011-03-03 | 2012-09-07 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
WO2012166560A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2013004842A2 (en) | 2011-07-06 | 2013-01-10 | Genmab A/S | Antibody variants and uses thereof |
EP2552957A1 (en) | 2010-03-29 | 2013-02-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
EP2560993A2 (en) | 2010-04-20 | 2013-02-27 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
EP0674652B1 (en) | 1992-12-16 | 2000-09-13 | Basf Aktiengesellschaft | Dolastatin analog |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
DE69434136T2 (en) | 1993-10-01 | 2005-12-01 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin DERIVATIVES |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
EP1149843A4 (en) * | 1999-01-28 | 2012-06-06 | Chugai Pharmaceutical Co Ltd | Substituted phenethylamine derivatives |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1531846A4 (en) | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
US7064211B2 (en) | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
EP1560574A4 (en) | 2002-04-23 | 2010-01-13 | Univ Ohio State | Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin |
ITMI20021391A1 (en) | 2002-06-25 | 2003-12-29 | Nicox Sa | NITRO-DERIVATIVES OF CYCLOOXYGENASE-2 INHIBITORS |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
CA2498759A1 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
WO2004047615A2 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Hemiasterlin affinity probes and their uses |
US7390910B2 (en) | 2003-08-08 | 2008-06-24 | Wyeth | Compounds for treating tumors |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
AU2004272132A1 (en) | 2003-09-15 | 2005-03-24 | The University Of British Columbia | Ceratamines A and B, and analogues, syntheses and pharmaceutical compositions thereof |
WO2005039492A2 (en) | 2003-10-22 | 2005-05-06 | The John Hopkins University | Improved combination bacteriolytic therapy for the treatment of tumors |
US7078562B2 (en) | 2004-01-19 | 2006-07-18 | Mitsubishi Gas Chemical Company, Inc. | Adamantane derivatives and resin compositions using the same as raw material |
EP2266622A3 (en) | 2004-08-26 | 2012-06-20 | Piramal Life Sciences Limited | Prodrugs containing novel bio-cleavable linkers |
CN101039701A (en) | 2004-08-26 | 2007-09-19 | 尼古拉斯皮拉马尔印度有限公司 | Prodrugs and codrusgs containing bio-cleavable disulfide linkers |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
BRPI0817881A2 (en) | 2007-10-10 | 2015-03-31 | Novartis Ag | Organic compounds and their uses |
WO2009059309A2 (en) | 2007-11-01 | 2009-05-07 | Panacea Pharmaceuticals, Inc. | Furin-cleavable peptide linkers for drug-ligand conjugates |
JP5562257B2 (en) | 2008-01-30 | 2014-07-30 | ピーリス アーゲー | Tear lipocalin mutein having affinity for tyrosine kinase of human C-MET receptor and method for obtaining the same |
PE20091623A1 (en) * | 2008-02-29 | 2009-11-19 | Array Biopharma Inc | 1H-PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS |
WO2009117531A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2010033207A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
DK2865387T3 (en) | 2008-11-21 | 2019-08-26 | Univ Copenhagen | Preparing an immune response |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
ES2532866T3 (en) | 2009-09-25 | 2015-04-01 | Astellas Pharma Inc. | Substituted amide compound |
WO2011154359A1 (en) | 2010-06-10 | 2011-12-15 | Bayer Pharma Aktiengesellschaft | Novel auristatin derivatives and use thereof |
CA2810706C (en) | 2010-09-24 | 2018-06-12 | Astellas Pharma Inc. | Substituted amide compound |
CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
EP2686337B1 (en) | 2011-03-16 | 2016-11-02 | Council of Scientific & Industrial Research | Oligopeptides and process for preparation thereof |
JP6161592B2 (en) | 2011-03-30 | 2017-07-12 | アリゾナ・ボード・オブ・リージェンツ, フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティArizona Board Of Regents, For And On Behalf Of Arizona State University | Auristatin tyramine phosphate and auristatin aminoquinoline derivatives and prodrugs thereof |
WO2012143495A2 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Novel binder-drug conjugates (adcs) and their use |
US20130190248A1 (en) | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
EP2776409B1 (en) | 2011-11-09 | 2016-02-03 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
US11787844B2 (en) | 2012-02-09 | 2023-10-17 | Var2 Pharmaceuticals Aps | Targeting of chondroitin sulfate glycans |
CN104640572B (en) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | Drug conjugates, coupling method, and application thereof |
US10800856B2 (en) | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
SG11201408494UA (en) | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
WO2014074658A1 (en) | 2012-11-09 | 2014-05-15 | Bristol-Myers Squibb Company | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
SG10201705150RA (en) | 2012-12-21 | 2017-07-28 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
KR102178606B1 (en) * | 2013-03-15 | 2020-11-13 | 자임워크스 인코포레이티드 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
SG11201604879QA (en) | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
MX2016007865A (en) | 2013-12-17 | 2017-01-11 | Novartis Ag | Cytotoxic peptides and conjugates thereof. |
KR102384740B1 (en) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | Sulfonamide-containing linkage systems for drug conjugates |
RU2714933C2 (en) | 2013-12-27 | 2020-02-21 | Займворкс Инк. | Var2csa-drug conjugates |
CN113416229A (en) | 2014-09-17 | 2021-09-21 | 酵活有限公司 | Cytotoxic and antimitotic compounds, and methods of use thereof |
US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
-
2014
- 2014-03-14 KR KR1020157029402A patent/KR102178606B1/en active IP Right Grant
- 2014-03-14 US US14/213,504 patent/US9522876B2/en active Active
- 2014-03-14 PT PT14763699T patent/PT2968440T/en unknown
- 2014-03-14 EA EA201591632A patent/EA029818B8/en unknown
- 2014-03-14 PL PL14763699T patent/PL2968440T3/en unknown
- 2014-03-14 JP JP2016503104A patent/JP6431038B2/en active Active
- 2014-03-14 NZ NZ71198214A patent/NZ711982A/en unknown
- 2014-03-14 TR TR2019/11139T patent/TR201911139T4/en unknown
- 2014-03-14 EP EP14763699.7A patent/EP2968440B1/en active Active
- 2014-03-14 AU AU2014228489A patent/AU2014228489B2/en active Active
- 2014-03-14 MX MX2015012868A patent/MX368258B/en active IP Right Grant
- 2014-03-14 WO PCT/US2014/029463 patent/WO2014144871A1/en active Application Filing
- 2014-03-14 CN CN201480027374.0A patent/CN105358174B/en active Active
- 2014-03-14 EP EP19174765.8A patent/EP3590922A1/en active Pending
- 2014-03-14 SG SG11201507619PA patent/SG11201507619PA/en unknown
- 2014-03-14 MY MYPI2015002339A patent/MY174813A/en unknown
- 2014-03-14 ES ES14763699T patent/ES2741207T3/en active Active
- 2014-03-14 DK DK14763699.7T patent/DK2968440T3/en active
- 2014-03-14 US US14/776,654 patent/US10201614B2/en active Active
- 2014-03-14 CN CN201910125160.1A patent/CN110143999B/en active Active
- 2014-03-14 CA CA2906784A patent/CA2906784C/en active Active
-
2015
- 2015-09-10 IL IL24152415A patent/IL241524B/en active IP Right Grant
- 2015-09-17 ZA ZA2015/06918A patent/ZA201506918B/en unknown
-
2016
- 2016-07-15 HK HK16108315.3A patent/HK1220140A1/en unknown
- 2016-07-21 HK HK16108733.7A patent/HK1220626A1/en unknown
-
2019
- 2019-02-11 US US16/273,045 patent/US11617777B2/en active Active
-
2023
- 2023-02-21 US US18/112,402 patent/US20230390354A1/en active Pending
Patent Citations (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012023A1 (en) | 1978-12-05 | 1980-06-11 | Claude Peter Windsor-Smith | Change speed gear |
WO1983003679A1 (en) | 1982-04-12 | 1983-10-27 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
EP0105360A1 (en) | 1982-04-12 | 1984-04-18 | Hybritech Incorporated | Antibodies having dual specificities, their preparation and uses therefor |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0171496A2 (en) | 1984-08-15 | 1986-02-19 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
EP0184187A2 (en) | 1984-12-04 | 1986-06-11 | Teijin Limited | Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric DNA encoding it |
EP0217577A2 (en) | 1985-09-12 | 1987-04-08 | Hybritech Incorporated | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5122368A (en) | 1988-02-11 | 1992-06-16 | Bristol-Myers Squibb Company | Anthracycline conjugates having a novel linker and methods for their production |
US5006652A (en) | 1988-08-08 | 1991-04-09 | Eli Lilly And Company | Intermediates for antibody-vinca drug conjugates |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5094849A (en) | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5387578A (en) | 1990-08-03 | 1995-02-07 | Farmitalia Carlo Erba S.R.L. | New linker for bioactive agents |
US5547667A (en) | 1990-08-03 | 1996-08-20 | Farmitalia Carlo Erba S.R.L. | Linker for bioactive agents |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5569825A (en) | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5708146A (en) | 1992-01-23 | 1998-01-13 | Bristol-Myers Squibb Company | Thioether conjugates |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5643573A (en) | 1993-03-30 | 1997-07-01 | Eli Lilly And Company | Antibody-drug conjugates |
US5665358A (en) | 1993-03-30 | 1997-09-09 | Eli Lilly And Company | Antibody drug-conjugates |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1996033211A1 (en) | 1995-04-20 | 1996-10-24 | University Of British Columbia | Biologically active peptides and compositions, their use |
US6103236A (en) | 1995-05-10 | 2000-08-15 | Kyowa Hakko Kogyo Co., Ltd. | Toxin conjugates |
US6638509B1 (en) | 1995-05-10 | 2003-10-28 | Kyowa Hakko Kogyo, Co., Ltd. | Toxin conjugates |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US7579323B1 (en) | 1997-12-19 | 2009-08-25 | The University Of British Columbia | Hemiasterlin analogs |
US6468522B1 (en) | 1999-07-22 | 2002-10-22 | University Of Medicine And Dentistry Of New Jersey | Controlled release of thioamide moiety-containing therapeutic agents |
US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
WO2002008180A1 (en) | 2000-07-24 | 2002-01-31 | Matsushita Electric Industrial Co., Ltd. | Bis(4-mercaptophenyl) sulfide derivatives, process for the preparation thereof and electronic components |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
WO2003068144A2 (en) | 2001-12-21 | 2003-08-21 | Immunogen, Inc. | Cytotoxic agents |
US7528152B2 (en) * | 2002-03-22 | 2009-05-05 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof in the treatment of cancer |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004016801A2 (en) | 2002-08-16 | 2004-02-26 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
WO2004026293A2 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2005077090A2 (en) | 2004-02-05 | 2005-08-25 | Seattle Genetics, Inc. | Improved methods of producing antibody conjugates |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
US20080305044A1 (en) * | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
WO2006110476A2 (en) | 2005-04-08 | 2006-10-19 | Medarex, Inc. | Cytotoxic compounds and conjugates comprising duocarmycins with cleavable substrates |
WO2007011968A2 (en) | 2005-07-18 | 2007-01-25 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
WO2007038658A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
WO2008083312A2 (en) | 2006-12-28 | 2008-07-10 | Medarex, Inc. | Chemical linkers and cleavable substrates and conjugates thereof |
WO2008103693A2 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
WO2009134976A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
WO2009134977A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Cross-linkers and their uses |
WO2009134952A2 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
WO2009157771A2 (en) | 2008-06-27 | 2009-12-30 | Merus B.V. | Antibody producing non-human mammals |
WO2010001251A2 (en) | 2008-07-02 | 2010-01-07 | Argen-X B.V. | Antigen binding polypeptides |
EP2326349A1 (en) | 2008-07-21 | 2011-06-01 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
EP2552957A1 (en) | 2010-03-29 | 2013-02-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
EP2560993A2 (en) | 2010-04-20 | 2013-02-27 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
WO2012116453A1 (en) | 2011-03-03 | 2012-09-07 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
WO2012166560A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2013004842A2 (en) | 2011-07-06 | 2013-01-10 | Genmab A/S | Antibody variants and uses thereof |
Non-Patent Citations (68)
Title |
---|
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", December 2000, WILEY |
"Fundamental Immunology", 1993, RAVEN PRESS |
"Remington: The Science and Practice of Pharmacy", 2000, PHILADELPHIA COLLEGE OF PHARMACY AND SCIENCE |
AGNEW, CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 |
AGRAWAL ET AL.: "Protocols for Oligonucleotide Conjugates", vol. 26, 1994, pages: 1 - 72 |
ANGEW. CHEM. INT. ED., vol. 49, 2010, pages 9422 - 9425 |
BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060 |
BERTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
BIRD, SCIENCE, vol. 242, 1988, pages 423 - 442 |
BOWEN ET AL., J. IMMUNOL., vol. 151, 1993, pages 5896 - 5906 |
BREITLING ET AL.: "Recombinant Antibodies", 1998, JOHN WILEY, AND SONS |
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24 |
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167 |
CARTER ET AL., J. HEMATOTHERAPY, vol. 4, 1995, pages 463 - 470 |
CHEMBIOCHEM, vol. 12, 2011, pages 1309 - 1312, Retrieved from the Internet <URL:http://www.synaffix.com/technology> |
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, INC., pages: 77 - 96 |
COLIGAN ET AL.: "Current Protocols in Protein Science", vol. 2, 2002, JOHN WILEY & SONS |
FRANCISCO ET AL., CANCER RES., vol. 60, 2000, pages 3225 - 3231 |
FRANKE ET AL., CANCER BIOTHER. RADIOPHARM., vol. 15, 2000, pages 459 - 476 |
GREEN, T.W.; P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY |
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
HIGUCHI, T. ET AL.: "Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "A.C.S. Symposium Series" |
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381 |
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281 |
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883 |
JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899 - 903 |
JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525 |
KABAT ET AL., J. IMMUNOLOGY, vol. 125, no. 3, 1980, pages 961 - 969 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTE OF HEALTH |
KIM ET AL., BIOCONJUGATE CHEMISTRY, vol. 21, no. 8, August 2010 (2010-08-01), pages 1513 - 1519 |
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 |
KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 - 79 |
LAGUZZA ET AL., J. MED. CHEM., vol. 32, no. 3, 1989, pages 548 - 555 |
LIU ET AL., J. IMMUNOL., vol. 139, 1987, pages 3521 - 3526 |
LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3439 - 3443 |
LONBERG; HUSZAR, INT. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 |
MCLEAN ET AL., J IMMUNOL., vol. 174, no. 8, 15 April 2005 (2005-04-15), pages 4768 - 4778 |
MCLEAN GR; OLSEN OA; WATT IN; RATHANASWAMI P; LESLIE KB; BABCOOK JS; SCHRADER JW: "Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response", J IMMUNOL., vol. 174, no. 8, 15 April 2005 (2005-04-15), pages 4768 - 4778, XP002505839 |
MERCHANT ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 677 - 681 |
MILSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539 |
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
MORRISON, SCIENCE, vol. 229, 1985, pages 1202 - 1207 |
MURRAY, SEMIN. ONCOL., vol. 27, 2000, pages 64 - 70 |
NISHIMURA ET AL., CANCER. RES., vol. 47, 1987, pages 999 - 1005 |
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214 |
OLSSON ET AL., METH. ENZYMOL., vol. 92, 1982, pages 3 - 16 |
PROC NATL ACAD SCI USA, vol. 93, no. 15, 1996, pages 7843 - 7848 |
QUAN; CARTER: "Anti-IgE and Allergic Disease", 2002, MARCEL DEKKER, article "The rise of monoclonal antibodies as therapeutics", pages: 427 - 469 |
RATAIN ET AL., PROC AM SOC CLIN ONCOL, vol. 22, 2003, pages 129 |
RODRIGUES ET AL., J. IMMUNOLOGY, vol. 151, 1993, pages 6954 - 6961 |
SHAW ET AL., J. NATL. CANCER INST., vol. 80, 1988, pages 1553 - 1559 |
SUN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 214 - 218 |
SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210 |
TALPIR, R. ET AL., TETRAHEDRON LETT., vol. 35, 1994, pages 4453 - 4456 |
TENG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 7308 - 7312 |
TRAIL ET AL., CANCER RESEARCH, vol. 57, 1997, pages 100 - 105 |
TRAIL ET AL., SCIENCE, vol. 261, 1993, pages 212 - 215 |
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659 |
VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534 |
WAHL ET AL., CANCER RES., vol. 62, no. 13, 2002, pages 3736 - 3742 |
WARD ET AL., NATURE, vol. 334, 1989, pages 544 - 554 |
WERBOVETZ ET AL.: "Selective Antimicrotubule Activity of N1-Phenyl-3,5-dinitro- 4,N-4-di-n- propylsulfanilamide ( GB -II-5) against Kinetoplastid Parasites", MOL PHARMACOL, vol. 64, 2003, pages 1325 - 1333, XP055281705 * |
WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449 |
YAMASHITA ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 5317 - 5322 |
ZASK ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 4353 - 4358 |
ZASK ET AL., J MED CHEM, vol. 47, 2004, pages 4774 - 4786 |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11617777B2 (en) | 2013-03-15 | 2023-04-04 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11560422B2 (en) | 2013-12-27 | 2023-01-24 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
AU2014373574B2 (en) * | 2013-12-27 | 2020-07-16 | Zymeworks Bc Inc. | Sulfonamide-containing linkage systems for drug conjugates |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
US10450378B2 (en) | 2014-09-17 | 2019-10-22 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10414822B2 (en) | 2014-09-17 | 2019-09-17 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11591405B2 (en) | 2014-09-17 | 2023-02-28 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
JP2021063124A (en) * | 2014-09-25 | 2021-04-22 | アンティコア バイオファーマ リミテッド | Biological materials and uses thereof |
US9636421B2 (en) | 2014-10-03 | 2017-05-02 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
EP3733209A1 (en) * | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
WO2016053107A1 (en) * | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
JP2017538666A (en) * | 2014-10-03 | 2017-12-28 | シンアフィックス ビー.ブイ. | Sulfamide linker, conjugate of sulfamide linker, and method of preparation |
CN112494657A (en) * | 2014-10-03 | 2021-03-16 | 西纳福克斯股份有限公司 | Sulfonamide linkers, conjugates thereof, and methods of making |
US10792369B2 (en) | 2014-10-03 | 2020-10-06 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US11850286B2 (en) | 2014-10-03 | 2023-12-26 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
CN107106701B (en) * | 2014-10-03 | 2020-11-06 | 西纳福克斯股份有限公司 | Sulfonamide linkers, conjugates thereof, and methods of making |
CN107106701A (en) * | 2014-10-03 | 2017-08-29 | 西纳福克斯股份有限公司 | Sulfonamide joint, its conjugate and preparation method |
US11510407B2 (en) | 2015-10-14 | 2022-11-29 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
US10694739B2 (en) | 2015-10-14 | 2020-06-30 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
US9986733B2 (en) | 2015-10-14 | 2018-06-05 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
JP2017200902A (en) * | 2016-02-08 | 2017-11-09 | シンアフィックス ビー.ブイ. | Novel antibody-conjugate with improved therapeutic index for targeting HER2 tumor and method for improving therapeutic index of antibody-conjugate |
JP2017197512A (en) * | 2016-02-08 | 2017-11-02 | シンアフィックス ビー.ブイ. | Novel antibody-conjugates with improved therapeutic index for targeting cd30 tumors and methods for improving therapeutic index of antibody-conjugates |
US10548986B2 (en) | 2016-03-02 | 2020-02-04 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
US10322192B2 (en) | 2016-03-02 | 2019-06-18 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
US9926285B2 (en) | 2016-03-22 | 2018-03-27 | Merck Sharp & Dohme Corp. | Allosteric modulators of nicotinic acetylcholine receptors |
US9840481B2 (en) | 2016-03-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Allosteric modulators of nicotinic acetylcholine receptors |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
US11795195B2 (en) | 2017-08-10 | 2023-10-24 | Sumitomo Pharma Co., Ltd. | Antibody-drug conjugates including hemiasterlin derivative |
WO2019031614A1 (en) | 2017-08-10 | 2019-02-14 | 大日本住友製薬株式会社 | Antibody-drug conjugates including hemiasterlin derivative |
WO2019031615A1 (en) | 2017-08-10 | 2019-02-14 | 大日本住友製薬株式会社 | Hemiasterlin derivatives and antibody-drug conjugates including same |
EP4321523A2 (en) | 2017-08-10 | 2024-02-14 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
US11845950B2 (en) | 2018-06-06 | 2023-12-19 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
RU2695787C1 (en) * | 2018-11-07 | 2019-07-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Use of the compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol for treating her2-positive tumors experimentally |
WO2020166600A1 (en) | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | Hemiasterlin derivative having cysteine residue |
US11603396B2 (en) | 2019-05-22 | 2023-03-14 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11802144B2 (en) | 2019-05-22 | 2023-10-31 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11679120B2 (en) | 2019-12-04 | 2023-06-20 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11766449B2 (en) | 2019-12-04 | 2023-09-26 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11771715B2 (en) | 2019-12-04 | 2023-10-03 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230390354A1 (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
AU2020230264B2 (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
BR112015023415B1 (en) | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, COMPOSITION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480027374.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14763699 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241524 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2016503104 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2906784 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/012868 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014763699 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014228489 Country of ref document: AU Date of ref document: 20140314 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591632 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20157029402 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015023415 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015023415 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150914 |